US20200286620A1 - Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of parkinsons disease, movement and neurological disorders, and chronic pain - Google Patents
Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of parkinsons disease, movement and neurological disorders, and chronic pain Download PDFInfo
- Publication number
- US20200286620A1 US20200286620A1 US16/884,701 US202016884701A US2020286620A1 US 20200286620 A1 US20200286620 A1 US 20200286620A1 US 202016884701 A US202016884701 A US 202016884701A US 2020286620 A1 US2020286620 A1 US 2020286620A1
- Authority
- US
- United States
- Prior art keywords
- disease
- patient
- data
- tests
- parkinson
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
-
- Y02A90/26—
Definitions
- Movement disorders are neurological conditions that affect the speed, fluency, quality, and ease of movement.
- Abnormal fluency or speed of movement may involve excessive or involuntary movement (hyperkinesia) or slowed or absent voluntary movement (hypokinesia).
- Another goal of the present disclosure is to make life better for those with Parkinson's disease, movement disorders, neurological disease, and/or chronic pain by measuring the efficacy of various treatments to treat the disease or disorder, delay its onset, and/or prevent it from developing.
- Another goal of the present disclosure is to overcome the lack of patient recruitment which can limit the amount and frequency of data collected, thereby restricting the full utility of the investigation.
- the ability to remotely collect data in real-time or near real-time that would normally involve physician/patient interactions will significantly improve patient recruitment as well as the kinds and frequency of data collection possible in an investigation.
- Assimilating and translating data under the present disclosure is designed for use by the physician or researcher and is potentially life altering for those with Parkinson's disease, neurological disease, movement disorders, and/or chronic pain, increasing the ability to diagnose and treat, assessing medication dosage and compliance, and longitudinally track the progression of Parkinson's disease, neurological disease, movement disorders, and/or chronic pain patient.
- This type of patient surveillance will ultimately serve to decrease morbidities associated with Parkinson's disease, neurological disease, movement disorders, and/or chronic pain, increase patient/physician contact, and will serve as an excellent research platform.
- FIG. 1 is a block diagram of a system for remote data gathering, monitoring, baseline staging, and treatment of Parkinson's disease, neurological diseases, and/or other movement disorders, in accordance with one embodiment of the present disclosure.
- the present system may optionally incorporate Health Insurance Portability and Accountability Act (HIPAA) compliant data security for all applicable aspects of the system including data access, data mining, data transmission, and data storage.
- HIPAA Health Insurance Portability and Accountability Act
- the modular architecture of the present disclosure will allow for easy upgrading to new standards in privacy as they become mandated or applicable.
- the basic test module will provide the clinician and researcher a baseline measurement from which to assess changes in Parkinson's disease status, and to assist in making decisions regarding medications or treatment approaches. It consists of a number of relatively simple tests that can be performed as many times as necessary either daily or multi-times per day. The test gathers the data in both go live and subjective form as it relates to the UPDRS #'s 1, 3, 4, 5, 7, 10, 12, 13, 14, 15, 16, 18, 20, 21, 22, 25, 32, 34, 40 and 41, (representing a total of 20 tests).
- the computer system may include clients and servers.
- a client and server are generally remote from each other and typically interact through a network, such as the described one.
- the relationship of client and server arises by virtue of computer programs running on the respective computers and having a client-server relationship to each other.
Abstract
Description
- This application claims the benefit of U.S. Provisional Patent Application No. 61/086,136 filed on Aug. 4, 2008, which is incorporated by reference herein in its entirety.
- This disclosure relates to early diagnosis, staging, assessment and treatment tools for Parkinson's disease (PD), movement disorders, neurological diseases, and/or chronic pain, designed to drive innovation and to best accelerate research into Parkinson's disease, movement disorders, neurological diseases, and/or chronic pain. The present disclosure facilitates improved access to patients suffering from such disorders along with innovative data capture methods designed to lead to improved therapies and assist in finding a cure for these disorders. The present disclosure is broadly applicable as a diagnosis and assessment tool for Parkinson's disease, movement disorders and many neurological diseases and chronic pain.
- Parkinson's disease (PD) is a chronic and progressive degenerative disease of the brain that impairs motor control, speech, and other functions. The disease is named after English physician James Parkinson, who gave a detailed description of it in an 1817 work titled, “An Essay on the Shaking Palsy”.
- Parkinson's disease belongs to a group of conditions called movement disorders. It is characterized by muscle rigidity, resting tremor (typically at about 5 Hz), slowing of movement (bradykinesia) and, in extreme cases, nearly complete loss of movement (akinesia). Secondary symptoms may include high level cognitive dysfunction, subtle language problems, and depression.
- In contrast to many other neurological disorders, the nature of the brain degeneration that produces Parkinson's disease has been well understood for decades. The symptoms are caused by loss of nerve cells that secrete dopamine in a tiny midbrain area called the substantia nigra. These nerve cells, for reasons that are not fully understood, are especially vulnerable to damage of various sorts, including drugs, disease, and head trauma. The term Parkinsonism is used for any process that destroys large numbers of these cells and thereby causes the same characteristic symptoms. Parkinson's disease, or more fully, idiopathic Parkinson's disease, is diagnosed when no specific physical cause for the loss of dopamine cells can be identified. This is the most common situation.
- The term Parkinsonism is used for symptoms of tremor, stiffness, and slowing of movement caused by loss of dopamine cells in the substantia nigra. “Parkinson's disease” is the synonym of “primary Parkinsonism”, i.e. isolated Parkinsonism due to a neurodegenerative process without any secondary systemic cause. In some cases, it would be inaccurate to say that the cause is “unknown” because a small proportion is caused by identifiable genetic mutations. It is possible for a patient to be initially diagnosed with Parkinson's disease but then to develop additional features requiring revision of the diagnosis.
- There are other disorders called Parkinson-plus diseases. These include: multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB). Lewy bodies are abnormal aggregates of protein that develop inside nerve cells. Most idiopathic Parkinson's disease patients also have Lewy bodies in their brain tissue, but the distribution is denser and more widespread in DLB. Even so, the relationship between Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies (DLB) might be most accurately conceptualized as a spectrum, with a discrete area of overlap between each of the three disorders. The natural history and role of Lewy bodies is little understood.
- These Parkinson-plus diseases may progress more quickly than typical idiopathic Parkinson disease. If cognitive dysfunction occurs before or very early in the course of the movement disorder then DLB may be suspected. Early postural instability with minimal tremor especially in the context of ophthalmoparesis should suggest PSP. Early autonomic dysfunction including erectile dysfunction and syncope may suggest MSA. The presence of extreme asymmetry with patchy cortical cognitive defects such as dysphasia and apraxias especially with “alien limb” phenomena should suggest CBD.
- The usual anti-Parkinson's medications are typically either less effective or not effective at all in controlling symptoms; patients may be exquisitely sensitive to neuroleptic medications like haloperidol. Additionally, the cholinesterase inhibiting medications have shown preliminary efficacy in treating the cognitive, psychiatric, and behavioral aspects of the disease, so correct differential diagnosis is important.
- Essential tremor may be mistaken for Parkinson's disease but lacks all other features besides tremor, and has particular characteristics distinguishing it from Parkinson's, such as improvement with beta blockers and alcoholic beverages (see http://en.wikipedia.org/wiki/Parkinson's_disease—cite_note—Jankovic2008-0). Wilson's disease (hereditary copper accumulation) may present with Parkinsonian features; young patients presenting with Parkinsonism or any other movement disorder are frequently screened for this rare condition, because it may respond to medical treatment. Typical tests are liver function, slit lamp examination for Kayser-Fleischer rings, and serum ceruloplasmin levels.
- Parkinson's disease affects movement (motor symptoms). Other typical symptoms include disorders of mood, behavior, thinking, and sensation (non-motor symptoms). Patients' individual symptoms may be quite dissimilar and progression of the disease is also distinctly individual.
- The cardinal symptoms of Parkinson's disease are:
-
- Tremor: normally 4-6 Hz tremor, maximal when the limb is at rest, and decreased with voluntary movement. It is typically unilateral at onset. This is the most apparent and well-known symptom though an estimated 30% of patients have little perceptible tremor; these are classified as akinetic-rigid.
- Rigidity: stiffness; increased muscle tone. In combination with a resting tremor, this produces a ratchety, “cogwheel” rigidity when the limb is passively moved.
- Akinesia/bradykinesia: absence of movement and slowness, respectively. Rapid, repetitive movements produce a dysrhythmic and decremental loss of amplitude.
- Postural instability: failure of postural reflexes, which leads to impaired balance and falls.
- Other motor symptoms include gait and posture disturbances:
-
- Shuffling: gait is characterized by short steps with feet barely leaving the ground, producing an audible shuffling noise. Small obstacles tend to cause the patient to trip.
- Decreased arm-swing.
- Turning “en bloc”: rather than the usual twisting of the neck and trunk and pivoting on the toes, Parkinson's disease patients keep their neck and trunk rigid, requiring multiple small steps to accomplish a turn.
- Stooped, forward-flexed posture: In severe forms, the head and upper shoulders may be bent at a right angle relative to the trunk (camptocormia).
- Festination: a combination of stooped posture, imbalance, and short steps. It leads to a gait that gets progressively faster and faster, often ending in a fall.
- Gait freezing: “freezing” is a manifestation of akinesia (an inability to move). Gait freezing is characterized by an inability to move the feet which may worsen in tight, cluttered spaces or when attempting to initiate gait.
- Dystonia (in about 20% of cases): abnormal, sustained, painful twisting muscle contractions, often affecting the foot and ankle (mainly toe flexion and foot inversion), which often interferes with gait.
- Speech and swallowing disturbances:
-
- Hypophonia: soft speech. Speech quality tends to be soft, hoarse, and monotonous. Some people with Parkinson's disease claim that their tongue is “heavy” or have cluttered speech.
- Monotonic speech.
- Festinating speech: excessively rapid, soft, poorly-intelligible speech.
- Drooling: most likely caused by a weak, infrequent swallow and stooped posture.
- Dysphagia: impaired ability to swallow; may lead to aspiration pneumonia.
- Other motor symptoms:
-
- Fatigue (up to 50% of cases).
- Masked faces (a mask-like face also known as hypomimia), with infrequent blinking.
- Difficulty rolling in bed or rising from a seated position.
- Micrographia (small cramped handwriting).
- Impaired fine motor dexterity and motor coordination.
- Impaired gross motor coordination.
- Akathisia: the inability to sit still.
- Parkinson's disease causes cognitive and mood disturbances, being in many cases related. Estimated prevalence rates of depression vary widely according to the population sampled and methodology used. Reviews of depression estimate its occurrence in anywhere from 20-80% of cases. Estimates from community samples tend to find lower rates than from specialist centres. Most studies use self-report questionnaires such as the Beck Depression Inventory, which may overinflate scores due to physical symptoms. Studies using diagnostic interviews by trained psychiatrists also report lower rates of depression. More generally, there is an increased risk for any individual with depression to develop Parkinson's disease at a later date. Seventy percent of individuals with Parkinson's disease diagnosed with pre-existing depression go on to develop anxiety. Ninety percent of Parkinson's disease patients with pre-existing anxiety subsequently develop depression, apathy or abulia.
- Cognitive disturbances include:
-
- Slowed reaction time: both voluntary and involuntary motor responses are significantly slowed.
- Executive dysfunction, characterized by difficulties in: differential allocation of attention, impulse control, set shifting, prioritizing, evaluating the salience of ambient data, interpreting social cues, and subjective time awareness. This complex is present to some degree in most Parkinson's patients; it may progress to:
- Dementia: a later development in approximately 20-40% of all patients, typically starting with slowing of thought and progressing to difficulties with abstract thought, memory, and behavioral regulation. Hallucinations, delusions and paranoia may develop.
- Short term memory loss: procedural memory is more impaired than declarative memory. Prompting elicits improved recall
- Non-motor causes of speech/language disturbance in both expressive and receptive language: these include decreased verbal fluency and cognitive disturbance especially related to comprehension of emotional content of speech and of facial expression.
- Difficulty deceiving others that links to prefrontal hypometabolism.
- Medication effects: some of the above cognitive disturbances are improved by dopaminergic medications, while others are actually worsened.
- Movement disorders are neurological conditions that affect the speed, fluency, quality, and ease of movement. Abnormal fluency or speed of movement (dyskinesia) may involve excessive or involuntary movement (hyperkinesia) or slowed or absent voluntary movement (hypokinesia).
- Movement disorders include the following conditions:
-
- Ataxia (lack of coordination, often producing jerky movements)
- Dystonia (causes involuntary movement and prolonged muscle contraction)
- Huntington's disease (also called chronic progressive chorea)
- Multiple system atrophies (e.g., Shy-Drager syndrome)
- Myoclonus (rapid, brief, irregular movement)
- Parkinson's disease
- Progressive supranuclear palsy (rare disorder that affects purposeful movement)
- Restless leg syndrome (RSD) and periodic limb movement disorders (PLMD)
- Tics (involuntary muscle contractions)
- Tourette's syndrome
- Tremor (e.g., essential tremor, resting tremor)
- Wilson disease (inherited disorder that causes neurological and psychiatric symptoms and liver disease).
- Common dystonias include spasmodic torticollis, which affects muscles of the head, face, and neck; and blepharospasm, which causes involuntary closing of the eyelids.
- Tourette's syndrome is an inherited disorder characterized by multiple motor and vocal tics (repeated muscle contractions). Symptoms of Tourette's syndrome usually develop during childhood or early adolescence. Patients with the disorder often develop behavioral problems such as hyperactivity, inattention, impulsivity, obsessions, and compulsions. In most cases, symptoms vary in frequency and in severity.
- Tics are involuntary muscle contractions that interrupt normal activities. They often are preceded by a strong sensation or urge that is temporarily relieved following the muscle contraction. Examples of common tics include the following: blinking, clearing the throat, facial twitching, grunting, shrugging the shoulders, and sighing.
- Movement disorders occur as a result of damage or disease in a region located at the base of the brain (basal ganglia). The basal ganglia are comprised of clusters of nerve cells (neurons) that send and receive electrical signals and are responsible for involuntary movement. Movement disorders may result from at least one of the following: age-related changes, environmental toxins, genetic disorders (e.g., Huntington's disease, Wilson disease), medications (e.g., antipsychotic drugs), metabolic disorders (e.g., hyperthyroidism), Parkinson's disease, and stroke.
- Neurologic Diseases are disorders of the brain, spinal cord and nerves throughout the body. Together they control all the workings of the body. When something goes wrong with a part of the nervous system, an individual may have trouble moving, speaking, swallowing, breathing or learning. The individual may also have problems with memory, senses or mood.
- Currently there are more than 600 neurologic diseases. Thus, neurological disorders are disorders that can affect the central nervous system (brain and spinal cord), the peripheral nervous system, or the autonomic nervous system. Major conditions include:
-
- behavioral/cognitive syndromes
- headache disorders such as migraine, cluster headache and tension headache
- epilepsy
- traumatic brain injury
- neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (Lou Gehrig's disease)
- cerebrovascular disease, such as transient ischemic attack and stroke
- sleep disorders
- cerebral palsy
- infections of the brain (encephalitis), brain meninges (meningitis), spinal cord (myelitis)
- infections of the peripheral nervous system
- neoplasms: tumors of the brain and its meninges (brain tumors); spinal cord tumors, tumors of the peripheral nerves (neuroma)
- movement disorders, such as Parkinson's disease, Huntington's disease, hemiballismus, tic disorder, and Tourette's syndrome
- demyelinating diseases of the central nervous system, such as multiple sclerosis, and of the peripheral nervous system, such as Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP)
- spinal cord disorders: tumors, infections, trauma, malformations (e.g., myelocele, meningomyelocele, tethered cord)
- disorders of peripheral nerves, muscle (myopathy) and neuromuscular junctions
- exciting injuries to the brain, spinal cord and peripheral nerves
- altered mental higher status, encephalopathy, stupor and coma
- speech and language disorders; functional symptoms, having no apparent physiological cause; and
- paraneoplastic neurological syndromes.
- Chronic Pain Overview:
- While acute pain is a normal sensation triggered in the nervous system to alert an individual to possible injury and the need to take care of the situation or issue, chronic pain is different. Chronic pain persists. Pain signals keep firing in the nervous system for weeks, months, even years. There may have been an initial mishap, e.g.: sprained back, serious infection, or there may be an ongoing cause of pain, e.g.: arthritis, cancer, ear infection, but some people suffer chronic pain in the absence of any past injury or evidence of body damage.
- Many chronic pain conditions affect older adults. Common chronic pain complaints include headache, low back pain, cancer pain, arthritis pain, neurogenic pain (pain resulting from damage to the peripheral nerves or to the central nervous system itself), psychogenic pain (pain not due to past disease or injury or any visible sign of damage inside or outside the nervous system).
- Medications, acupuncture, local electrical stimulation, and brain stimulation, as well as surgery, are some treatments for chronic pain. Some physicians use placebos, which in some cases has resulted in a lessening or elimination of pain. Psychotherapy, relaxation and medication therapies, biofeedback, and behavior modification may also be employed to treat chronic pain. Many people with chronic pain may be helped if they understand the causes of pain and the many and varied steps that can be taken to undo what chronic pain has instantiated.
- This disclosure is directed to systems and methods, including computer-implemented systems and methods, to facilitate one or more of the following: diagnosis of disease; baseline and progression of disease staging; data gathering (e.g., biochemical, physical, neurological, and cognitive data gathering), including remote data gathering; monitoring, including remote monitoring; and treatment of patients suffering from or suspected of suffering from one or more of Parkinson's disease (PD) movement disorders, neurological diseases, and chronic pain. More particularly, this disclosure is directed to web-based and Internet systems and methods for remote implementation of the same.
- It is a goal of the present disclosure to provide systems and methods, including computer-implemented systems and methods, to facilitate one or more of the following: diagnosis of disease; baseline and progression of disease staging; data gathering (e.g., biochemical, physical, neurological, and cognitive data gathering), including remote data gathering; monitoring, including remote monitoring; and treatment of patients suffering from or suspected of suffering from one or more of Parkinson's disease (PD) movement disorders, neurological diseases, and chronic pain. It is an additional goal to provide web-based and Internet systems and methods for remote implementation of the same.
- Another goal of the present disclosure is to provide systems and methods for providing remote data gathering, monitoring, baseline staging, and treatment of Parkinson's disease and, more particularly, to systems and methods utilizing a web based interface and communicating via the internet, a wide area network, a local area network, or any other remote communication method.
- Another goal of the present disclosure is to provide systems and methods for providing remote data gathering, monitoring, baseline staging, and treatment of movement disorders and, more particularly, to systems and methods utilizing a web based interface and communicating via the internet, a wide area network, a local area network, and any other remote communication method. Movement disorders include akathisia sometimes referred to as acathisia, akinesia including akinetic mutism; coma; Angelman syndrome; ataxia including spinocerebella degredation; athetosis, bradykinesia; chorea including Sydenham's chorea and Huntington's disease; cerebral palsy; dystonia, blepharospasm; mogigraphia, sometimes referred to as writer's cramp; spasmodic torticollis; dyskinesias, including paroxysmal dyskinesias, paroxysmal kinesigenic dyskinesia, paroxysmal non-kinesigenic dyskinesia, paroxysmal exertion-induced dyskinesia, paroxysmal hypnogenic dyskinesia, and tardive dyskinesia; Fragile X-associated tremor; ataxia syndrome; geniospasm; Joubert syndrome; Machado-Joseph disease; multiple system atrophy; striatonigral degeneration; myoclonus; neuroacanthocytosis; neurodegeneration with brain iron accumulation; paroxysmal choteoathetosis disease; restless leg syndrome; spasm, including infantile spasm; stereotypic movement disorders; stereotypy; tic disorder; Tourette's syndrome; tremor; essential tremor; and Wilson's disease.
- Another goal of the present disclosure is to provide systems and methods for providing remote data gathering, monitoring, baseline staging, and treatment of neurological diseases and, more particularly, to systems and methods utilizing a web based interface and communicating via the internet, a wide area network, a local area network, and any other remote communication method. Neurological diseases include Landau-Kleffner syndrome; acute disseminated encephalomyelitis; attention deficit hyperactivity disorder; Holmes-Adie syndrome; adrenoleukodystrophy; leukodystrophy; Pelizaeus-Merzbacher disease; metachromatic leukodystrophy; agenesis of the corpus callosum; agnosia; Aicardi syndrome; neurological complications of AIDS; Alexander disease; Alpers' disease; alternating hemiplegia; amyotrophic lateral sclerosis; Von Hippel-Lindau disease; antiphospholipid syndrome; aphasia; apraxia; arachnoid cysts; arachnoiditis; chiari malformation; arteriovenous malformation; Asperger syndrome; autism and autism spectrum disorders; dysautonomia; back pain; Barth syndrome; Batten disease; myotonia; myotonia congenita; Behcet's disease; Bell's palsy; monomelic amyotrophy; meralgia paresthetica, Binswanger's disease; incontinentia pigmenti; brachial plexus injuries; orthostatic hypotension; brain and spinal tumors; tuberous sclerosis; cerebral aneurysm; traumatic brain injury; Brown-Sequard syndrome; Kennedy's disease; spinal muscular atrophy; cerebral autosomal dominant arteriopathy with sub-cortical infarcts and leukoencephalopathy; carpal tunnel syndrome; complex regional pain syndrome; cerebral cavernous malformation; spinal cord injury; central cord syndrome; central pain syndrome; central pontine myelinolysis; cephalic disorders; lipid storage diseases; Tay-Sachs disease; Niemann-Pick disease; Farber's disease; cerebellar degeneration; Wernicke-Korsakoff syndrome; Sotos syndrome; cerebral hypoxia; Charcot-Marie tooth disease; neuroacanthocytosis; chronic inflammatory demyelinating polyneuropathy; postural tachycardia syndrome; Coffin Lowry syndrome; cerebro-oculo-facio-skeletal syndrome; colpocephaly; Moebius syndrome; congenital myasthenia; congenital myopathy; corticobasal degeneration; vasculitis syndromes of the central and peripheral nervous systems; craniosynostosis; Creutzfeldt-Jakob disease; Cushing's syndrome; opsoclonus myoclonus; Dandy-Walker syndrome; subacute sclerosing panencephalitis; septo-optic dysplasia; dementia, including multi-infarct dementia, frontotemporal dementia, subcortical dementia, dementia with Lewy bodies; dentate cerebellar ataxia; dyssynergia cerebellaris; myoclonica; dermatomyositis; developmental dyspraxia; Devic's syndrome; neuromyelitis optica; diabetic neuropathy; diffuse sclerosis; Schlder's disease; Dravet syndrome; dysgraphia; dyslexia; early infantile epileptic encephalopathy; Ohtahara syndrome; encephalitis; meningitis; encephalopathy; Sturge-Weber syndrome; epilepsy; Todd's paralysis; Fahr's syndrome; familial periodic paralyses; febrile seizures; Miller Fisher syndrome; hypotonia; foot drop; Friedreich's ataxia; Gerstmann's syndrome; Gerstmann-Straussler-Scheinker disease; giant axonal neuropathy; Guillain-Barré syndrome; hemifacial spasm; hereditary neuropathies; hereditary spastic paraplegia; Refsum disease; tropical spastic paraparesis; hydrocephalus; hydromyelia; hypertonia; inclusion body myositis; infantile neuroaxonal dystrophy; inflammatory myopathies; Whipple's disease; Isaac's syndrome; Kearns-Sayre syndrome; Klippel-Trenaunay syndrome; Klüver-Bucy syndrome; Lambert-Eaton myasthenic; Wallenberg's syndrome; Leigh's disease; Lennox-Gastaut syndrome; Lesch-Nyhan syndrome; lipoid proteinosis; lissencephaly; neurological sequelae of lupus; megalencephaly; Menkes disease; microcephaly; transient ischemic stroke; mitochondrial myopathies; motor neuron diseases; Moyamoya disease; multifocal motor neuropathy; multiple sclerosis; muscular dystrophy; myasthenia gravis; myopathy; thyronic myopathy; neuroleptic malignant syndrome; neuronal migration disorders; schizencephaly; neurosarcoidosis; neurotoxicity; paraneoplastic syndromes; stiff-person syndrome; Parry-Romberg syndrome; peripheral neuropathy; periventricular leukomalacia; porencephaly; post-polio syndrome; primary lateral sclerosis; tabes dorsalis; progressive multifocal leukoencephalopathy; Alpers' disease; progressive supranuclear palsy; Rasmussen's encephalitis; Rett syndrome; Sandhoff disease; shaken baby syndrome; sleep apnea; spasticity; spinal cord infarction; syncope; hydromyelia; tethered spinal cord syndrome; thoracic outlet syndrome; transverse myelitis; Troyer syndrome; and whiplash.
- Another goal of the present disclosure is to provide systems and methods for providing remote data gathering, monitoring, baseline staging, and treatment of chronic pain and pain management and, more particularly, to systems and methods utilizing a web based interface and communicating via the internet, a wide area network, a local area network, and any other remote communication method.
- Another goal of the present disclosure is to make life better for those with Parkinson's disease, movement disorders, neurological disease, and/or chronic pain by measuring the efficacy of various treatments to treat the disease or disorder, delay its onset, and/or prevent it from developing.
- Another goal of the present disclosure is to make an early diagnosis of Parkinson's disease, movement disorders, and neurological disease, and/or chronic pain, which allows both the patient and caregivers time to make choices that maximize quality of life; select an appropriate medical team; afford a better chance of benefiting from treatment and/or participate in studies or experimental treatments which tend to focus on early stage Parkinson's disease, movement disorders, and/or neurological diseases; lessen anxieties about unknown problems; enhance safety and security by planning for diminished or impaired physical or mental capacity; and provide more time to plan for the future.
- Yet another goal of the present disclosure is to remotely acquire fully validated clinical data and assessments of Parkinson's disease, movement disorders, neurological disease symptoms, and/or chronic pain patients from a greater population and cross-section of patients, at significantly lower cost with types and level of data previously unavailable to the physician or researcher, especially from a remote access location. Improved access to patients and innovative data capture will ultimately lead to improved therapies and render assistance in the search for therapies for Parkinson's disease, movement disorders, neurological diseases, and/or chronic pain.
- Yet another goal of the present disclosure is to aid in differential diagnosis of Parkinson's disease, movement disorders, neurological diseases, and chronic pain from other disorders.
- Yet another goal of the present disclosure is to detect memory loss of recently learned information, thereby enabling early detection of the onset of dementia related to Parkinson's disease, neurological diseases, movement disorders, and/or chronic pain.
- Yet another goal of the present disclosure is to detect difficulty with performing everyday tasks such as playing simple games, dressing, cooking meals, or basic hygiene. Measuring the amount and type of difficulty with performing everyday tasks allows for discrimination between normal age related thought process degradation and Parkinson's symptoms or progression of other movement disorders, neurological diseases, and/or chronic pain. Periodic measurement of difficulty with performing everyday tasks will provide another metric for gauging the progression of the disease or disorder.
- Yet another goal of the present disclosure is to detect difficulty with speech. Voice recognition will be utilized to detect the loss of memory for simple words or the use of unusual words in place of the correct word or words. By measuring the amount and type of difficulty with speech the present disclosure, one is able to discriminate between normal age related speech impairment and Parkinson's disease symptoms or other movement disorders, neurological diseases, and/or chronic pain. Periodic measurement of difficulty with speech will provide yet another metric for gauging the progression of the disease or disorder.
- Yet another goal of the present disclosure is to detect difficulty with abstract thinking. One or more tests comprising a series of tasks are utilized to test abstract thinking skills which may be compared against a standard or known baseline. Periodic measurement of abstract thinking skills will provide yet another metric for gauging the progression of the disease or disorder.
- Yet another goal of the present disclosure is to detect changes in personality and to distinguish this from normal changes in personality from an individual's age to symptoms related to Parkinson's disease, neurological disease, movement disorders, and/or chronic pain. Periodic measurement of personality, e.g.: by using standard assays or questionnaires, will provide yet another metric for gauging the progression of the disease or disorder.
- Yet another goal of the present disclosure is to detect changes in mood or behavior which is another symptom of Parkinson's disease, other neurological diseases, movement disorders, and/or chronic pain and to distinguish this from normal changes in mood or behavior. Periodic measurement of mood or personality swings will provide yet another metric for gauging the progression of the disease or disorder.
- Yet another goal of the present disclosure is to assess risk factors for developing Parkinson's disease, neurological diseases, movement disorders, and/or chronic pain, such as age, family history, genetics (both risk and deterministic genes), traumatic head injury, high blood pressure, heart disease, stroke, diabetes and high cholesterol, weight, tobacco and excess alcohol consumption, physical exercise, mental exercise, and social interactions.
- Yet another goal of the present disclosure is to provide an easy to access, Health Insurance Portability and Accountability Act (HIPAA) compliant, fully comprehensive medical and psychological data and timelines for the primary care physician, neurologists, psychiatrists, and psychologists, and other authorized medical care professionals for the prophylactic treatment of Parkinson's disease, neurological diseases, movement disorders, and/or chronic pain.
- Yet another goal of the present disclosure is to overcome the difficulties in recruitment of a sufficient number of Parkinson's disease, neurological disease, movement disorder, and/or chronic pain patients for clinical studies who fit acceptance criteria and expected patient compliance. By remotely collecting data in batch mode, real-time, or near real-time that would normally involve physician/patient interactions, affords a significant improvement in patient recruitment as well as the kinds and frequency of data collection possible in an investigation.
- Yet another goal of the present disclosure is to remotely acquire improved and fully validated clinical data and assessments of Parkinson's disease, neurological disease, movement disorder, and/or chronic pain symptoms, from a broad population and cross-section of patients, at significantly lower cost. This data type and level of data has to date been unavailable to the physician or researcher, especially from a remote access location. This type of data capture will ultimately aid in transforming how certain types of clinical research is conducted. Improved access to patients and innovative data capture will ultimately lead to improved therapies and render assistance in the search for a cure for Parkinson's disease, neurological diseases, movement disorders, and/or chronic pain.
- Another goal of the present disclosure is to overcome the traditional hurdles for the recruitment of a sufficient number of patients who fit acceptance criteria, along with patient compliance any clinical study, including those in Parkinson's disease, neurological disease, movement disorders, and/or chronic pain. In addition, the elimination or reduction in the quantity of on-site physician interactions and testing is a significant benefit of the present disclosure. Indeed, traditional on-site testing and interactions has been the only way in which Parkinson's disease patients have been assessed up until the present disclosure.
- Another goal of the present disclosure is to overcome the lack of patient recruitment which can limit the amount and frequency of data collected, thereby restricting the full utility of the investigation. The ability to remotely collect data in real-time or near real-time that would normally involve physician/patient interactions will significantly improve patient recruitment as well as the kinds and frequency of data collection possible in an investigation. Assimilating and translating data under the present disclosure is designed for use by the physician or researcher and is potentially life altering for those with Parkinson's disease, neurological disease, movement disorders, and/or chronic pain, increasing the ability to diagnose and treat, assessing medication dosage and compliance, and longitudinally track the progression of Parkinson's disease, neurological disease, movement disorders, and/or chronic pain patient. This type of patient surveillance will ultimately serve to decrease morbidities associated with Parkinson's disease, neurological disease, movement disorders, and/or chronic pain, increase patient/physician contact, and will serve as an excellent research platform.
- Yet another goal of the present disclosure is to assimilate and translate data remotely acquired by the present disclosure for use by the physician or researcher, will increase the ability to diagnose and treat, assessing medication dosage and compliance, and longitudinally track the progression of Parkinson's disease, neurological disease, movement disorders, and/or chronic pain patient. This type of patient surveillance will ultimately serve to decrease morbidities associated with many of these diseases and disorders, increase patient/physician contact, and will serve as an excellent research platform.
- Yet another goal of the present disclosure is to provide an easily accessible “in-home” web based administration of mental status testing, including but not limited to the mini mental state examination and the “mini-cognitive” test that will allow frequent (diurnal, daily, weekly, monthly) monitoring of a patients mental state and automatically trigger warnings or alarms for patients that miss or fail their tests.
- Yet another goal of the present disclosure is to provide an easily accessible “in-home” web based administration of the Unified Parkinson's Disease Rating Tests, in whole, in part, incrementally, and/or on a predefined schedule by the patient, health care provider, doctor, or clinical researcher.
- Yet another goal of the present disclosure is to provide both standard and customizable tests tailored to a patient, group of patients, or clinical study that allows for the appropriate frequency, type, and duration of testing and inclusion of appropriate test elements. The customization can be performed by a health care provider, health professional, doctor, or clinical researcher as appropriate to the type and use of data required.
- Yet another goal of the present disclosure is to remotely gather data with the aid on an online health care provider, health professional, doctor, or clinical researcher available through interactive audio, video text, graphics, or any other media used singly or in any combination. The interaction may be full duplex or half duplex.
- Yet another goal of the present disclosure is to allow for testing that is fully self administered by the patient or health care provider, as well as providing a means to deploy “man-in-the-loop” tele-testing with real-time patient/physician interaction for special situations or increased functionality to provide maximum flexibility in the kinds of testing that can be utilized, all while preserving the autonomous remote location data collection capabilities of the system.
- Yet another goal of the present disclosure is to provide systems and methods for providing remote data gathering, monitoring, baseline staging, and treatment of Parkinson's disease and, more particularly, to systems and methods utilizing a web based interface and communicating via the internet, a wide area network, a local area network, and any other remote communication method.
- The above and other goals and advantages of the present disclosure will be apparent upon consideration of the following detailed description, taken in conjunction with accompanying drawings, in which like reference characters refer to like parts throughout, and in which:
-
FIG. 1 is a block diagram of a system for remote data gathering, monitoring, baseline staging, and treatment of Parkinson's disease, neurological diseases, and/or other movement disorders, in accordance with one embodiment of the present disclosure. -
FIGS. 2a, 2b and 2c present a flow diagram of a system for remote data gathering, monitoring, baseline staging, and treatment of Parkinson's disease, neurological diseases, and other movement disorders, in accordance with another embodiment of the present disclosure. -
FIG. 3 is a block diagram of a Patient Remote Interface for remote data gathering, monitoring, baseline staging, and treatment of Parkinson's disease, neurological diseases, and other movement disorders, in accordance with yet another embodiment of the present disclosure. -
FIG. 4 is a block diagram of a Patient Remote Interface with interface drivers and web browser for remote data gathering, monitoring, baseline staging, and treatment of Parkinson's disease, neurological diseases, and other movement disorders, in accordance with yet another embodiment of the present disclosure. -
FIGS. 5a, 5b, 5c and 5d are a flow diagram of a Mini Mental State Examination for remote data gathering, monitoring, baseline staging, and treatment of Parkinson's disease, neurological diseases, and other movement disorders, in accordance with another embodiment of the present disclosure. -
FIGS. 6a-e is a standard Unified Parkinson's disease Rating Scale. -
FIGS. 7a-b is a standard Unified Parkinson's disease Rating Scale Data Form. -
FIGS. 8a-g is a web implementation of the Unified Parkinson's Disease Rating Scale and associated level for use in remote data gathering, monitoring, baseline staging, and treatment of Parkinson's disease, neurological diseases, and other movement disorders, in accordance with another embodiment of the present disclosure. -
FIGS. 9a-d is a representative Summary Protocol for feasibility of one embodiment of the present disclosure of a web based-assessment tool for the determination of baseline staging, data gathering and monitoring of early, middle, and late stage Parkinson's disease. -
FIG. 10 is a block diagram of a computing system that can be used in connection with the data acquisition models and computer-implemented methods described in this document. - The present disclosure is directed to systems and methods, including computer-based systems and methods for providing one or more remote data gathering, monitoring, diagnosis, baseline and progression of disease staging, and treatment methods for Parkinson's disease, neurological diseases, movement disorders, and/or chronic pain and, more particularly, to systems and methods utilizing a web based interface and communication via the internet, a wide area network, a local area network, or any other remote communication method.
- In the following description, it is to be understood that system elements having equivalent or similar functionality are designated with the same reference numerals in the Figures. It is to be further understood that the present disclosure may be implemented in various forms of displays, hardware, software, firmware, networks or combinations thereof. In particular, the system modules described herein are preferably implemented in software as application programs that are executable by, e.g., a general purpose computer or any machine or device having any suitable and preferred microprocessor architecture.
- Preferably, the present disclosure is implemented on computer platforms including hardware such as one or more central processing units (CPU), a random access memory (RAM), and input/output (I/O) interface(s). The computer platform may also include an operating system and microinstruction code. The various processes and functions described herein may be either part of the microinstruction code or application programs which are executed via the operating system. In addition, various other peripheral devices may be connected to one or more computer platforms, such as accelerometers; gyroscopes magentometers; global positioning receivers and processing units; video cameras and video capture devices, such as web cameras, laser imaging radars, displays and touch input screens; speakers and other audio annunciators; microphones and other audio capture devices; capacitive contact pads and strain gauges; writing pads; touch pads; network interfaces and additional data storage devices; and printing devices.
- It is to be further understood that, because some of the constituent system components described herein are preferably implemented as software modules, hardware devices, and network interconnections, the actual system connections shown in the Figures may differ depending upon the manner in which the systems are programmed or implemented. Given the teachings herein, one of ordinary skill in the related art will be able to contemplate these and similar implementations or configurations of the present disclosure.
- Although illustrative embodiments have been described herein with reference to the accompanying drawings, it is to be understood that the present disclosure is not limited to those precise embodiments, and that various other changes and modifications may be affected therein by one skilled in the art without departing from the scope or spirit of the disclosure. All such changes and modifications are intended to be included within the scope of the disclosure as defined by the appended claims.
- Referring now to
FIG. 1 , a block diagram illustrates a system for remote data gathering, monitoring, baseline staging, and treatment of Parkinson's disease, movement disorders, neurological diseases, and/or chronic pain comprised of aRemote Patient Interface 105, Health CareProvider Remote Interface 110,Physician Remote Interface 115,Researcher Remote Interface 120, and Insurer orFiduciary Remote Interface 125, which are operatively connected to aRemote Data Center 160 via theInternet 130 or any other means of remote connection. - It should be noted that the Patient, Health Care Provider, Physician, Researcher, and Insurer or Fiduciary Remote Interfaces may transmit data to, or receive data from, the Remote Data Center by any form of data transmission or via storage media. Transmission systems include, but are not limited to wide area networks, local area networks, wireless networks, cellular telephone transmission, satellite transmission, personal area networks (Bluetooth®), telephone dial-up interfaces, analog signals or digital signals via copper wire, fiber optics, and wireless including all portions of the spectrum such as visible, infrared, ultraviolet, ultrasonic, and radio frequency. Transmission systems may also include the physical delivery of memory storage devices including memory sticks, and all other forms of non-volatile and quasi-non-volatile memory devices.
- In addition, the Patient, Health Care Provider, Physician, Researcher, and Insurer or Fiduciary Remote Interfaces may transmit data to, or receive data from each other directly utilizing an appropriate of routing or addressing system via any form of data transmission. Advantageously, the information transmitted may be retained indefinitely or for some prescribed period of time by the transmitting and or receiving party for record keeping purposes and/or transmitted to the data center or another central repository of information for additional record keeping.
- The
remote patient interface 105 provides: a portal to the datacenter application server 150, performs one or more suites of tests as prescribed by the physician or healthcare provider, and securely transmits the results of the tests back to theapplication server 150. In one embodiment, open source PGP encryption to authenticate the identity of users and encrypt personal medical data so it cannot be stolen or duplicated by anyone else. In addition, encrypted digital signatures ensure that the data cannot be altered once it's electronically “signed”. Alternate encryption and validation technologies such as coviant diplomat transaction manager or other commercially or available encryption packages may be utilized if so desired. - It should be noted that Remote Patient Interface transmitting patient information may be part of a broader multi-purpose computing or network device. For example, the Patient Remote Interface may be hosted on an iPhone®, smartphone or any other personal digital assistant (PDA) or mobile computing device, a laptop computer, a desktop computer, or any device with a user interface and program capability, such as a cable box with a remote control.
- The Healthcare
Provider Remote interface 110, thePhysician Remote Interface 115, theResearcher Remote Interface 120, and the Insurer orFiduciary Remote Interface 125 each provide portals to the Data Center Application Server. - In one embodiment of the present disclosure, any computer or device with a web browser and internet access may function as a Healthcare Provider, or Insurer or Fiduciary Remote Interface.
- The
Physician Remote Interface 115 allows patients to be added and removed from the system along with management of passwords and access privileges. More significantly, Physician Remote Interface provides access to raw and processed data collected from patient tests and can provide various types of reports and graphs to be generated based upon a specific patient's tests results and test histories. In addition, a physician can order, prescribe, or construct any desired series of tests on a one time or periodic basis. - The Healthcare
Provider Remote Interface 110 allows limited access to one or more patient's data predicated upon specified privileges. For example, the healthcare provider may only be able to see patient compliance with various tests and test schedules. In addition, it will allow the healthcare provider to administer the tests to one or more patients. - The
Researcher Remote Interface 120 allows provides access to raw and processed data collected from patient tests and can provide various types of reports and graphs to be generated based upon a one or more patient tests result and test histories. In addition, a researcher can aggregate or download large quantities of data from multiple patients based upon specific profiles or selection criteria for conducting research into Parkinson's disease, neurological diseases, movement disorders, and/or chronic pain. The data may be accessed on an anonymous basis or by specific patient. - The Fiduciary or
Insurer Remote Interface 125 provides for the ability to send or receive billing information, pay bills, or process insurance claims. Patient health information and test results may be restricted to tests performed and testing dates for HIPAA compliance. - The
data center 160 is comprised of a means for receiving and transmitting appropriate data such as an interface to theinternet 130, a means for selecting only data beneficially intended for the present disclosure such as arouter 135, and optionally, one ormore firewalls 140 or other devices for protection from malicious or inadvertent attacks. Thedata center 160 will authenticate system users and sessions (e.g.: patients, healthcare providers, physicians, researchers, fiduciaries and insurers), maintain system user profiles and user information via aweb server 145 or software or hardware with equivalent functionality, administer tests via anapplication server 150 or software or hardware with equivalent functionality, and create a database of results from some or all patient tests via adatabase server 155 or software or hardware with equivalent functionality, and generate reports based upon tests or data collected on one or more patients via theapplication server 150. Advantageously, thedata center 160 will provide for automated back-up and recovery. - Administration functions will also be available, including system maintenance, maintaining system access privileges, and collecting various types of system performance and billing/payment information.
- Data center functions may be implemented in a wide variety of architectures including all functions on a single CPU running on a single operating system to complex distributed functionality in a large load balanced data center. In one embodiment of the present disclosure, the data center architecture consists of one or more of the following open source components including the Linux operating system. Apache web server, PHP scripting language, Code Igniter PHP framework, jQuery DHTML Library PostgreSQL database, and open source PGP encryption. The Linux operating system may be utilized to host the all of the applications needed to implement the data center. The data center system will be architected in a modular fashion allowing the various components to be run on a single computer or across multiple computers to provide rapid scalability.
- In one embodiment of the present disclosure, all or part of the data gathering, monitoring, baseline staging, and treatment system advantageously employs a modular architecture for rapid prototyping, validation, and deployment. A scalable architecture and user platforms may rely on open source or and commercially available or proprietary software, hardware and development and maintenance tools. This facilitates the addition of new tests and enhanced technologies while expediting prototyping and deployment.
- The
web server 145 will serve web pages to users of thesystem including Patients 105,Healthcare Providers 110,Physicians 115,Researchers 120, Fiduciaries andInsurers 125 via their respective remote interfaces. Additionally, data obtained during patient tests maybe uploaded to thedata center 160 via Firefox® or other web browser. The PHP scripting language in combination with the jQuery DHTML Library and the Code Igniter PHP framework will provide for interactive web pages that dynamically created utilizing information stored in the PostgreSQL database. For example, patients may see different homepages than doctors and researchers. Additionally, different patients may run through different sets of tests as prescribed. The PostgreSQL database will store at a minimum, the User Access Control List (ACL), Patient Profile, Patient Test Results, System Logging Information, Patient/Doctor Login Dates, Login IP Addresses. Logout Dates, Patient Profile Changes, and related information. - The present system may optionally incorporate Health Insurance Portability and Accountability Act (HIPAA) compliant data security for all applicable aspects of the system including data access, data mining, data transmission, and data storage. The modular architecture of the present disclosure will allow for easy upgrading to new standards in privacy as they become mandated or applicable.
- Referring now to
FIGS. 2a, 2b, and 2c , a flow diagram illustrates a system for remote data gathering, monitoring, baseline staging, and treatment of Parkinson's disease, movement disorders, neurological diseases, and/or chronic pain in accordance with another embodiment of the present disclosure. - As shown in
FIG. 2 , aRemote Patient Interface 201 requests login to the data center. Biometric or any other form ofPatient Identification 202 is optionally utilized for patient authentication. Other techniques, such as IP address and phone numbers, may also be utilized. If thelogin 203 is successful, the session is started 204. If the login is not successful, more retries may be attempted 205 and the login is retried 203. If no more retries are available 205, then a test is performed to see if the system can operate inlocal capacity 207. If local capability is available, then a local session is started for later download to the server ordata center 208. If local capability is not available, then the login process can be optionally retried 209, 201. - If login is successful and a session is started 204, the web server pushes a
welcome page 210, which is optionally personalized. The patient then initiates a first test sequence ortherapy 211. The web server the pushes the first test ortherapy sequence 212 to the patient interface. The test or therapy results and optionally times are reported back to thedata center 213. A check is performed to see if there are any additional tests or therapies to be performed 214. If no additional tests or therapies are to be performed, then a session end is requested 215 and the session is ended 216. If additional tests or therapies are required 214, then the next test or therapy sequence is initiated 218. The web server then pushes the next test ortherapy sequence 219 and the results are subsequently logged, optionally with times, and reported to the data center. - If login is not successful 203, then an optional test is performed to see of more retries are available 205. If more retries are available, then a login retry may be attempted 206. If more retries are not available, or if the patient wishes to operate in local mode only, a test is performed to see if local capability is available 207. If local capability is not available, then the only option available would be to restart the
login process 209. If a local session is available 207, then a local session is started for later download to the server/data center 208. - If a local session is started 208, the local application that essentially performs the function of the web server and data logging in the local environment is then started 221. The
local application 221 is optionally personalized. The patient then initiates a first test sequence ortherapy 222. The application runs the first test ortherapy sequence 223 to the patient interface. The test or therapy results, and optionally times, are logged for later reporting back to thedata center 224. A check is performed to see if there are any additional tests or therapies to be performed 225. If no additional tests or therapies are to be performed, then a try is attempted to report the test or therapy results to thedata center 226. Several retries may be attempted 227. If no more retries are available, the session is ended 228. If additional tests or therapies are required, then the next test or therapy sequence is initiated 231. The application then executes the next test ortherapy sequence 232 and the results are subsequently logged, optionally withtimes 233, for later reporting to the data center. - It should be noted that it is not necessary that the Patient Remote Interface operate in an interactive web based mode. Indeed, the system could always work in the local environment and report results to the data center in batch mode.
- Referring now to
FIG. 3 , a block, diagram illustrates a Patient Remote Interface for remote data gathering, monitoring, baseline staging, and treatment of Parkinson's disease, neurological diseases, movement disorders, and/or chronic pain in accordance with yet another embodiment of the present disclosure. The Remote Patient Interface gathers data (e.g., biochemical, physical, neurological, cognitive data) via one or more means of interfacing and/or interacting with one or more patients and then transmits the acquired data in raw or processed form via any means to the data center or to one or more remote interfaces. Any known assay may be used to acquire the data gathered. - As shown the remote patient platform hardware/
software device 300 interfaces with a variety of input and output devices. As shown, input devices for data acquisition from the patient may include one or more of the following: a keypad; touch screen input orother input device 305; a video acquisition device, such as a camera, webcam, orlaser imaging radar 310; an audio capture device, such as a microphone, preamp, and analog todigital converter 315; awriting pad 320; akinematic orientation tracker 325 which may be comprised of one or more gyroscopes, one or more accelerometers, a magnetometer, an optical motion/position sensing systems, a microwave motion/position sensing system, or any other mechanism, device, or stimulus sensing technology capable of sensing patient motion in any part of the patient's body. In one embodiment, a 3-axis gyro/accelerometer package, preferably with a wireless interface that acquires 3-axis attitude and acceleration information, along with pitch, roll, and yaw rates, may be utilized. - In addition, a global
positioning system receiver 330 may be utilized to acquire patient location information or motion of the patient's location or any part of the body or appendage. The global positioning system may consist of one or more receivers along with various types of position augmentation devices, such as a wide area augmentation system or other form of position/motion sensing. - Temperature monitors 335 may be employed for sensing of either external or internal body temperatures. The sensing technology may be any means, including contact temperature sensors, including solid state sensors, infrared remote sensing, and temperature sensor systems, that employ active or passive scanning.
- Blood pressure sensors and various forms of
blood chemistry monitoring 340 may be employed, utilizing either invasive or non-invasive monitoring techniques. Techniques utilized for blood pressure monitoring may rely on traditional cuff wraps or, more advantageously, pulse wave velocity which calculates blood pressure by measuring the pulse at two points along an artery. In addition, data from the kinematic orientation/motion sensor 325 may be employed concurrently with a pulse wave velocity blood pressure monitoring to compensate for blood pressure inaccuracies due to motion or orientation. - Electrocardiography (EKG/ECG) and/or electroencephalography (EEG) sensing 345 may be employed to gather data on cardiac and brain activity, respectively. A multitude of small portable EKG and EEG devices with USB or other data interfaces are widely available in the marketplace,
- A biometric or any other form of
security device 350, such as a retinal scanner, voice recognition, electronic or mechanical lock and key, may be utilized for restricting access to one or more patients, care givers, doctors, clinicians, and/or other personnel. - In one embodiment of the present disclosure, the
patient platform 300 may be a general purpose touchscreen computer running hosted on a Microsoft Windows Vista® operating system with the framework of the test application implemented using JavaScript® and will be hosted in a Mozilla Firefox® web browser. The JavaScript® code base will be stored and loaded from the data center's web server upon initiation of a test session by the patient. Microsoft Visual Studio C++ ® will be used to develop Windows® Services that will act as proxies for physical input devices. Windows® Services will be responsible for providing a robust and seamless interface to the JavaScript® application, while also handling initialization, error handling, and results reporting for their respective input devices. The JavaScript® application will communicate with the Windows® Services via a TCP/IP connection and SOAP (http://en.wikipedia.org/wiki/SOAP), an XML based communication protocol, with the data payload encrypted and authenticated by open source PGP encryption. - Output and stimulus devices include a
visual display 355; anaudio stimulus device 360, such as headphones or speaker system; one or moreforce stimulus devices 365 to test muscle strength, range of motion, and other physical properties; anolfactory stimulus device 370 for sense of smell; atouch stimulus device 375 for measuring nerve sensitivity and reflex responses; athermoception stimulus device 380 for temperature perception testing; a taste stimulus device fortaste sensitivity 385; and one ormore network interfaces 390 which may be wired, wireless, cellular, infrared, microwave, or any other form of data transmission and reception, or any combination thereof. -
FIG. 4 illustrates the interface drivers utilized to interface the various sensors and actuators in the Remote Patient Interface in one embodiment of the present disclosure. As shown, thepatient platform 300 may be a general purpose touchscreen computer running hosted on a Microsoft Windows Vista® operating system with the framework of the test application implemented using JavaScript® hosted in a Mozilla Firefox® web browser. As shown, all sensor and stimulus devices may utilize standard device drivers, such as Windows® Services. - Depending upon system implementation and the desire to process data remotely, the drivers utilized may also be the previously recited standard drivers that are available from various commercial suppliers of the sensors and actuators/feedback devices or they may be fully custom drivers written to support specific sensor/feedback functions or data processing functions, or some combination thereof. In particular, high bandwidth output
devices video acquisition 310,audio capture 315, and a kinematic orientation/motion tracker may have drivers or embedded applications that preprocess the data. By way of example, during a test for tremors on a limb, the data may be processed to give statistics on the frequency and magnitude of tremors rather than raw data from the gyros and accelerometers. The data processing functions may take place in the Device Driver Kalman Estimator andWindows® Service 425. -
FIGS. 5a, 5b, and 5c is a flowchart of a Mini Cognition Test. A Mini Cognition Test is initiated 501 and the Patient Remote Interface speaks three words selected from a prescribed list. The list may be selected based upon a variety of factors, including patient's age and education. The patient interface begins recording and, optionally, analyzing the words which will be repeated by thepatient 503. The patient interface then requests that the same three words be spoken by thepatient 504. The patient then attempts to speak the same threewords 505. A test is performed to see if the words are spoken 506. If yes, the results are reported or logged 511. If no, then a check is performed see if the test has timed out 507 (time limit reached). If no timeout has occurred, the words spoken test is continued 506. If there is atimeout 507, then the failure is reported or logged along with any optional analysis results 508. The patient interface may then query the patient for astatus 509. If the patent requests a retry, then the system again checks for words spoken 506. If the patient does not request a retry, then no retry is logged or reported 515. - After the results have been logged or reported 511, a touchscreen, writing pad or other user interface is enabled as appropriate to acquire drawn
clock data 512. The patient interface then requests that the patient draw aclock 513. The patient then attempts to draw aclock 514. A test is performed to see if the clock has been drawn 516. If “no”, then a test is performed to see if a timeout has occurred 517. If a timeout has occurred, then the failure is reported along with any related data analysis and results 518. The patient interface may then query the patient forstatus 519. If the patent requests a retry 520, then the system again checks for the drawnclock 516. If the patient does not request a retry, then no retry is logged or reported 521. If a clock has been drawn 516, the results are logged or reported 522. - The patient interface begins recording and, optionally, analyzing the words which will be repeated by the
patient 523. The patient interface then requests a repeat of the same three words that were requested earlier 524. The patient then attempts to speak the same threewords 525. A test is performed to see if the words are spoken 526. If yes, the results are reported or logged 532. If no, then a check is performed see if the test has timed out 527 (time limit reached). If no timeout has occurred, the words spoken test is continued 525. If there is atimeout 527, then the failure is reported or logged along with any optional analysis results 528. The patient interface may then query the patient for astatus 529. If the patent requests a retry, then the system again checks for words spoken 530. If the patient does not request a retry, then no retry is logged or reported 531. -
FIGS. 6a, 6b . 6 c, 6 d, and 6 e represent one version of the standard Unified Parkinson's disease Rating Scale which was designed to be administered in person, face to face, by a trained physician, clinician, or health care provider. - The Unified Parkinson's Disease Rating Scale is a rating scale used to follow the longitudinal course of Parkinson's disease. It is made up of the following sections: Mentation, behavior, and mood, Activities of daily living, Motor, and Complications of therapy.
- These sections are to be evaluated by interview and clinical observation. Some sections require multiple grades assigned to each extremity. Clinicians and researchers alike currently use the UPDRS and the motor section in particular to follow the progression of Parkinson's disease in a patient. Following the UPDRS scores over time provides insight into the patient's disease progression. For instance, Michael J. Fox's symptoms started with a slight tremor, so his motor score would have been less than 10. For most patients, the “mentation, behavior and mood” scores increase later in the disease, but there is a subset for who those symptoms develop early on.
- Diagnosis of Parkinson's disease thus presently relies on a neurological examination conducted by and review of a patient's medical history by interviewing and observing a patient in person using the Unified Parkinson's Disease Rating Scale and the patient's medical history.
- Parkinson's disease may be difficult to diagnose accurately, especially in the early stages. Early signs and symptoms may be dismissed by the physician or clinician administering the tests as part of the normal aging process since nearly all of the tests presently used are subjective. The present disclosure provides a means for garnering quantitative scientific data which may be utilized to diagnose the presence of disease or disorder and differentially diagnose and track the progression of Parkinson's disease from other diseases or disorders. In addition, for many diseases or disorders, a patient may not exhibit symptoms consistently. For example, in the case of Parkinson's disease, there may be only signs with or without symmetry; there may be no bradykinesia; or there may be atypical signs, such as postural, rather than rest, tremor, mild rigidity, a lack of progression of symptoms over time, and a lack of response to normal treatments such as Levodopa. The ability to acquire data more frequently at the patient's convenience, or at specific times, or a prescribed periodic basis, or when on or off medications, or at specific times of the day or night, or when the patient is exhibiting specific symptoms will greatly aid in Parkinson's research and the diagnosis of specific patients.
-
FIGS. 7a and 7b are a standard scoring sheet for the Unified Parkinson's Disease Rating Scale. As shown, the results are segregated by on and off medications and the results are also summarized by best and worst for the modified Hoehn and Yahr Staging, ranging from Stage 0 (which is no signs of the disease) to Stage 5 (which is wheelchair bound or bedridden unless aging). Summary results are also provided for the Activities of Daily Living ranging from 100% completely independent (able to do chores without slowness, difficulty or impairment, essentially normal, unaware of any difficulty) to 0% (vegetative functions, such as swallowing, bladder and bowel functions, are not functioning, bedridden). -
FIGS. 8a-g present a detailed test methodology which represents a modified version of the Unified Parkinson's Disease Rating Scale in accordance with one implementation of the present disclosure. As shown, the Remote Patient Interface implements various tests as prescribed by the physician or caregiver. As shown, there are three levels of use, Basic. Complex, and Comprehensive.FIGS. 8a-g are not intended to show all possibilities or indeed to implement all tests, but rather to show one representative implementation of a strata of Remote Patient Interface Testing. - It should be noted that in
FIGS. 8a-g that the basic test suite includes only those tests checked under basic. The complex test suite includes both the basic test suite and those test checked under complex. Likewise, the comprehensive test suite includes the complex test suite plus those test checked under comprehensive, thus the basic, complex, and comprehensive checked tests are included under the comprehensive test suite. - In one embodiment of the present disclosure, clinical validation of a system for baseline staging, data gathering, monitoring and treatment of Parkinson's disease, an initial selection of UPDRS or another fully standardized and widely practiced test is utilized to eliminate the variability associated with a new or not widely understood Assessment Protocol while focusing clinical test efforts on technology validation and simultaneously. As shown in
FIGS. 8a-g of the present disclosure, the present implementation of the UPDRS is constructed as a three level test suite which are designated as basic, complex, and comprehensive. These categories primarily reflect the organization of the questions comprising the UPDRS in terms of two factors: (1) the degree to which major data collection modalities would be needed to implement in remote testing and (2) relevance across a wide range of stages of Parkinson's disease so as to maximize the information conveyed. - The basic test module will provide the clinician and researcher a baseline measurement from which to assess changes in Parkinson's disease status, and to assist in making decisions regarding medications or treatment approaches. It consists of a number of relatively simple tests that can be performed as many times as necessary either daily or multi-times per day. The test gathers the data in both go live and subjective form as it relates to the UPDRS #'s 1, 3, 4, 5, 7, 10, 12, 13, 14, 15, 16, 18, 20, 21, 22, 25, 32, 34, 40 and 41, (representing a total of 20 tests).
- The complex tests will allow the clinician and researcher to more closely examine a greater set of symptom parameters. The complex test module includes UPDRS tests from the basic test module along with those that correspond to the UPDRS #'s 6, 8, 17, 19, 22, 23, 26, 27, 33 and 35 (for a total of 30 tests).
- The comprehensive test incorporates all levels of the UPDRS including those of the basic and complex test modules along with those from the UPDRS corresponding to #'s 2, 9, 11, 28, 29, 30, 31, 35, 36, 37, 38, 42 (a total of 42 tests). The comprehensive test can be utilized for a remote baseline examination or an examination of one complete specific area of the body. For example, a representative clinical study will utilize a longitudinal prospective study of 30 patients over 6 months. (10 with early, 10 with middle, and 10 with late stage Parkinson's disease as determined by the Hoehn and Yahr staging).
- In one embodiment of the present disclosure, availability of commercial off-the-shelf sensors and actuator is essential for rapid product development and deployment. However, in all cases the technology exists for implementing each of the 42 questions of the standard UPDRS (
FIG. 6 ) remotely. -
FIGS. 9a-d present one embodiment of a full clinical protocol with the Detailed Test Methodology shown inFIGS. 8a-c . The present test methodology employs measurements that involve both motor and non-motor aspects of the UPDRS. The choice of tests to implement in one embodiment of the clinical protocol is based on (1) relevance across a wide range of stages of Parkinson's disease and (2) the desire to validate major data collection modalities (inertial measurements, video capture, audio capture, computer based questionnaires and reaction time monitoring, walking pads, handwriting tablets) to demonstrate flexibility for integration of multiple technologies. The process of integrating various data collection modalities will also provide a basic structure on which to develop and integrate other testing modules or technologies in future efforts to expand and adapt this off-site data collection solution. - As shown in
FIGS. 8a-c , a variety of testing methodologies and devices are utilized, including questionnaires with short term memory shapes, words, and colors; voice capture for physician analysis or optional automated analysis; use of commercial signature verification; gait analysis systems; accelerometers or kinematic motion and position sensing; video capture for later physician or automated analysis; force stimulation and force feedback systems; dynamometers; and automated blood pressure analyzers. -
FIG. 10 is a schematic diagram of acomputer system 1000. Thesystem 1000 can be used for the operations described in association with any of the computer-implement methods described previously, according to one embodiment. Thesystem 1000 is intended to include various forms of digital computers, such as laptops, desktops, workstations, personal digital assistants, servers, blade servers, mainframes, and other appropriate computers. Thesystem 1000 may also include mobile devices, such as personal digital assistants, cellular telephones, smartphones, and other similar computing devices. Additionally, the system can include portable storage media, such as universal serial bus (USB) flash drives. For example, the USB flash drives may store operating systems and other applications. The USB flash drives may include input/output components, such as a wireless transmitter or USB connector that may be inserted into a USB port of another computing device. - The
system 1000 includes aprocessor 1010, amemory 1020, astorage device 1030, and an input/output device 1040. Each of thecomponents system bus 1050. Theprocessor 1010 is capable of processing instructions for execution within thesystem 1000. The processor may be designed using any of a number of architectures. For example, theprocessor 1010 may be a CISC (Complex Instruction Set Computers) processor, a RISC (Reduced Instruction Set Computer) processor, or a MISC (Minimal Instruction Set Computer) processor. - In one embodiment, the
processor 1010 is a single-threaded processor. In another embodiment, theprocessor 1010 is a multi-threaded processor. Theprocessor 1010 is capable of processing instructions stored in thememory 1020 or on thestorage device 130 to display graphical information for a user interface on the input/output device 1040. - The
memory 1020 stores information within thesystem 1000. In one embodiment, thememory 1020 is a computer-readable medium. In one embodiment, thememory 1020 is a volatile memory unit. In another embodiment, thememory 1020 is a non-volatile memory unit. - The
storage device 1030 is capable of providing mass storage for thesystem 1000. In one embodiment, thestorage device 1030 is a computer-readable medium. In various different embodiments, thestorage device 1030 may be a floppy disk device, a hard disk device, an optical disk device, or a tape device. - The input/
output device 1040 provides input/output operations for thesystem 100. In one embodiment, the input/output device 1040 includes a keyboard and/or pointing device. In another embodiment, the input/output device 1040 includes a display unit for displaying graphical user interfaces. - The features described can be implemented in digital electronic circuitry, or in computer hardware, firmware, software, or in combinations of them. The apparatus may be implemented in a computer program product tangibly embodied in an information carrier, e.g., in a machine-readable storage device for execution by a programmable processor; and method steps can be performed by a programmable processor executing a program of instructions to perform functions of the described embodiments by operating on input data and generating output. The described features may be implemented advantageously in one or more computer programs that are executable on a programmable system including at least one programmable processor coupled to receive data and instructions from, and to transmit data and instructions to, a data storage system, at least one input device, and at least one output device. A computer program is a set of instructions that can be used, directly or indirectly, in a computer to perform a certain activity or bring about a certain result. A computer program can be written in any form of programming language, including compiled or interpreted languages, and it can be deployed in any form, including as a stand-alone program or as a module, component, subroutine, or other unit suitable for use in a computing environment.
- Suitable processors for the execution of a program of instructions include, by way of example, both general and special purpose microprocessors, and the sole processor or one of multiple processors of any kind of computer. Generally, a processor will receive instructions and data from a read-only memory or a random access memory or both. The essential elements of a computer are a processor for executing instructions and one or more memories for storing instructions and data. Generally, a computer will also include, or be operatively coupled to communicate with, one or more mass storage devices for storing data files; such devices include magnetic disks, such as internal hard disks and removable disks; magneto-optical disks; and optical disks. Storage devices suitable for tangibly embodying computer program instructions and data include all forms of non-volatile memory, including by way of example semiconductor memory devices, such as EPROM, EEPROM, and flash memory devices; magnetic disks such as internal hard disks and removable disks; magneto-optical disks; and CD-ROM and DVD-ROM disks. The processor and the memory can be supplemented by, or incorporated in, ASICs (application-specific integrated circuits).
- To provide for interaction with a user, the features may be implemented on a computer having a display device such as a CRT (cathode ray tube) or LCD (liquid crystal display) monitor for displaying information to the user and a keyboard and a pointing device such as a mouse or a trackball by which the user can provide input to the computer.
- The features may be implemented in a computer system that includes a back-end component, such as a data server, or that includes a middleware component, such as an application server or an internet server, or that includes a front-end component, such as a client computer having a graphical user interface or an internet browser, or any combination of them. The components of the system can be connected by any form or medium of digital data communication such as a communication network. Examples of communication networks include a local area network (LAN), a wide area network (WAN), peer-to-peer networks (having ad-hoc or static members), grid computing infrastructures, and the internet.
- The computer system may include clients and servers. A client and server are generally remote from each other and typically interact through a network, such as the described one. The relationship of client and server arises by virtue of computer programs running on the respective computers and having a client-server relationship to each other.
- Although illustrative embodiments have been described herein with references to the accompanying drawings, it is to be understood that the present disclosure is not limited those precise embodiments, and that various other changes and modifications may be affected therein by one skilled in the art without departing from the spirit or scope of the disclosure as defined by the appended claims.
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/884,701 US20200286620A1 (en) | 2008-08-04 | 2020-05-27 | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of parkinsons disease, movement and neurological disorders, and chronic pain |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8613608P | 2008-08-04 | 2008-08-04 | |
US12/535,676 US10776453B2 (en) | 2008-08-04 | 2009-08-04 | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
US16/884,701 US20200286620A1 (en) | 2008-08-04 | 2020-05-27 | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of parkinsons disease, movement and neurological disorders, and chronic pain |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/535,676 Continuation US10776453B2 (en) | 2008-08-04 | 2009-08-04 | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200286620A1 true US20200286620A1 (en) | 2020-09-10 |
Family
ID=42286201
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/535,676 Active US10776453B2 (en) | 2008-08-04 | 2009-08-04 | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
US16/884,701 Abandoned US20200286620A1 (en) | 2008-08-04 | 2020-05-27 | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of parkinsons disease, movement and neurological disorders, and chronic pain |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/535,676 Active US10776453B2 (en) | 2008-08-04 | 2009-08-04 | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
Country Status (1)
Country | Link |
---|---|
US (2) | US10776453B2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10940187B2 (en) | 2011-04-21 | 2021-03-09 | Curemark, Llc | Method of treatment of schizophreniform disorder |
US11016104B2 (en) | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US11020064B2 (en) * | 2017-05-09 | 2021-06-01 | LifePod Solutions, Inc. | Voice controlled assistance for monitoring adverse events of a user and/or coordinating emergency actions such as caregiver communication |
US11033563B2 (en) | 2005-08-30 | 2021-06-15 | Curemark, Llc | Use of lactulose in the treatment of autism |
US11045527B2 (en) | 2008-03-13 | 2021-06-29 | Curemark, Llc | Method of diagnosing preeclampsia or pregnancy-induced hypertension |
US11147982B1 (en) | 2021-05-05 | 2021-10-19 | Kambix Innovations, Llc | Method and system for thermal stimulation of targeted neural circuits for neurodegenerative disorders |
US11235038B2 (en) | 2008-04-18 | 2022-02-01 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US11357835B2 (en) | 2009-01-06 | 2022-06-14 | Galenagen, Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US11364287B2 (en) | 2012-05-30 | 2022-06-21 | Curemark, Llc | Methods of treating celiac disease |
US11404062B1 (en) | 2021-07-26 | 2022-08-02 | LifePod Solutions, Inc. | Systems and methods for managing voice environments and voice routines |
US11410655B1 (en) | 2021-07-26 | 2022-08-09 | LifePod Solutions, Inc. | Systems and methods for managing voice environments and voice routines |
US11419821B2 (en) | 2009-04-13 | 2022-08-23 | Curemark, Llc | Enzyme delivery systems and methods of preparation and use |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
US20070053895A1 (en) | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
US8030002B2 (en) * | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
US11363982B1 (en) * | 2008-10-14 | 2022-06-21 | Great Lakes Neurotechnologies Inc. | Method and system for quantifying movement disorder symptoms |
CA2747611C (en) | 2009-01-06 | 2019-09-17 | Curemark Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
US20100268551A1 (en) * | 2009-04-20 | 2010-10-21 | Apdm, Inc | System for data management, analysis, and collaboration of movement disorder data |
WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
US9872637B2 (en) | 2010-04-21 | 2018-01-23 | The Rehabilitation Institute Of Chicago | Medical evaluation system and method using sensors in mobile devices |
CN102525386B (en) * | 2010-12-17 | 2015-11-25 | 世意法(北京)半导体研发有限责任公司 | Capsule endoscope |
KR20120070287A (en) * | 2010-12-21 | 2012-06-29 | 주식회사 넷블루 | Recognition rehabilitation service system |
CN103998394B (en) | 2011-08-01 | 2016-08-17 | 德诺弗科学公司 | Cell capture system and using method |
US20130035579A1 (en) | 2011-08-02 | 2013-02-07 | Tan Le | Methods for modeling neurological development and diagnosing a neurological impairment of a patient |
US9426051B2 (en) * | 2012-03-15 | 2016-08-23 | Mckesson Financial Holdings | Method and apparatus for facilitating remote health monitoring of a computerized healthcare system |
US9622660B2 (en) | 2012-05-25 | 2017-04-18 | Emotiv Lifesciences Inc. | System and method for enabling collaborative analysis of a biosignal |
US9867548B2 (en) | 2012-05-25 | 2018-01-16 | Emotiv, Inc. | System and method for providing and aggregating biosignals and action data |
US9763592B2 (en) | 2012-05-25 | 2017-09-19 | Emotiv, Inc. | System and method for instructing a behavior change in a user |
US9171131B2 (en) * | 2012-06-22 | 2015-10-27 | Integrated Deficit Examinations, LLC | Device and methods for mobile monitoring and assessment of clinical function through sensors and interactive patient responses |
GB201212544D0 (en) * | 2012-07-13 | 2012-08-29 | Univ York | Device to determine extent of dyskinesia |
CN103581247A (en) * | 2012-07-30 | 2014-02-12 | 杭州洱海科技有限公司 | Method for testing distributed type Web based on cloud computing environment |
EP3027110A4 (en) | 2013-07-30 | 2017-06-28 | Emotiv Lifesciences, Inc. | Wearable system for detecting and measuring biosignals |
WO2015023997A1 (en) * | 2013-08-16 | 2015-02-19 | Papandrea John | Personalized patient experience system |
US9924899B2 (en) * | 2013-09-09 | 2018-03-27 | Alexis Pracar | Intelligent progression monitoring, tracking, and management of parkinson's disease |
US9445769B2 (en) * | 2013-12-06 | 2016-09-20 | President And Fellows Of Harvard College | Method and apparatus for detecting disease regression through network-based gait analysis |
CN106662992A (en) * | 2014-05-16 | 2017-05-10 | 科赛普特治疗学股份有限公司 | Systems and methods of managing treatment of a chronic condition by symptom tracking |
US9720810B2 (en) * | 2014-12-09 | 2017-08-01 | Google Inc. | Device cloud monitoring and stability |
US10108264B2 (en) | 2015-03-02 | 2018-10-23 | Emotiv, Inc. | System and method for embedded cognitive state metric system |
US20160262681A1 (en) * | 2015-03-13 | 2016-09-15 | At&T Intellectual Property I, L.P. | Detecting depression via mobile device data |
WO2016161301A1 (en) * | 2015-04-01 | 2016-10-06 | Tiranoff Louise | Video databases and methods for detection or diagnosis of neurodevelopment disorders |
CN114647779A (en) * | 2015-08-12 | 2022-06-21 | 爱康迪健康规划服务股份有限公司 | Information processing apparatus, information processing method, and recording medium |
WO2017202839A1 (en) * | 2016-05-23 | 2017-11-30 | Koninklijke Philips N.V. | System and method for early detection of transient ischemic attack |
US10537701B2 (en) * | 2016-07-05 | 2020-01-21 | International Business Machines Corporation | Alleviating movement disorder conditions using unmanned aerial vehicles |
US11450433B2 (en) | 2017-02-02 | 2022-09-20 | Becare Link, Llc | System and method for remote diagnosis of disease progression |
US10079074B1 (en) * | 2017-03-16 | 2018-09-18 | Prize4Life | System for monitoring disease progression |
US10701713B2 (en) * | 2017-04-11 | 2020-06-30 | Viasat, Inc. | Return link prioritization of selective events on a mobile platform |
AU2018337654A1 (en) * | 2017-09-19 | 2020-04-09 | Daniel Glasner | Method and apparatus for determining health status |
AU2018350984A1 (en) * | 2017-10-17 | 2020-05-07 | Satish Rao | Machine learning based system for identifying and monitoring neurological disorders |
US20200373019A1 (en) * | 2018-01-31 | 2020-11-26 | ETS Platform, LLC | Preventive care platform for interactive patient monitoring |
US20200406000A1 (en) * | 2018-03-08 | 2020-12-31 | Citizen Watch Co., Ltd. | Heart rate control device |
US11521740B2 (en) | 2018-06-06 | 2022-12-06 | International Business Machines Corporation | Natural language processing of a motion alphabet for unsupervised clinical scoring |
US11783949B2 (en) | 2018-11-30 | 2023-10-10 | Ariel Precision Medicine, Inc. | Methods and systems for severity calculator |
JP6749624B1 (en) * | 2019-03-27 | 2020-09-02 | 株式会社 バイオミメティクスシンパシーズ | System for erectile dysfunction patients |
GB201909176D0 (en) * | 2019-06-26 | 2019-08-07 | Royal College Of Art | Wearable device |
CN110689966B (en) * | 2019-08-26 | 2022-05-24 | 泰康保险集团股份有限公司 | System and method for internet outpatient service |
US11684299B2 (en) | 2019-12-17 | 2023-06-27 | Mahana Therapeutics, Inc. | Method and system for remotely monitoring the psychological state of an application user using machine learning-based models |
CN111012312B (en) * | 2019-12-25 | 2024-01-30 | 中国科学院合肥物质科学研究院 | Portable parkinsonism bradykinesia monitoring and intervention device and method |
CN111292844B (en) * | 2020-01-21 | 2023-03-21 | 桂林医学院附属医院 | Parkinson disease condition monitoring system |
US11610663B2 (en) | 2020-05-29 | 2023-03-21 | Mahana Therapeutics, Inc. | Method and system for remotely identifying and monitoring anomalies in the physical and/or psychological state of an application user using average physical activity data associated with a set of people other than the user |
US11967432B2 (en) | 2020-05-29 | 2024-04-23 | Mahana Therapeutics, Inc. | Method and system for remotely monitoring the physical and psychological state of an application user using altitude and/or motion data and one or more machine learning models |
CN111870253A (en) * | 2020-07-27 | 2020-11-03 | 上海大学 | Method and system for monitoring condition of tic disorder disease based on vision and voice fusion technology |
WO2022086784A1 (en) * | 2020-10-22 | 2022-04-28 | Mahana Therapeutics, Inc. | Methods and systems for treating gastrointestinal and inflammatory health conditions using prescription digital therapeutics in combination with other therapies |
CN113744838A (en) * | 2021-09-08 | 2021-12-03 | 杭州康晟健康管理咨询有限公司 | Parkinson's motion rehabilitation intelligent management system |
KR102414191B1 (en) * | 2021-12-01 | 2022-06-28 | 의료법인 명지의료재단 | Infectious disease treatment with mobility clinic vehicle |
CN117238483B (en) * | 2023-11-10 | 2024-02-27 | 哈尔滨海鸿基业科技发展有限公司 | Child cerebral palsy diagnosis equipment |
Family Cites Families (242)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US29752A (en) * | 1860-08-28 | Improvement in seeding-machines | ||
US28689A (en) * | 1860-06-12 | Door-spring | ||
BE491927A (en) | 1948-10-30 | |||
US3002883A (en) | 1959-07-29 | 1961-10-03 | Dow Chemical Co | Disinfectant compositions |
GB928654A (en) | 1960-10-25 | 1963-06-12 | Philips Nv | Improvements in or relating to the production of pancreatin |
US3322626A (en) * | 1963-06-13 | 1967-05-30 | Pannett Products Inc | Medicinal composition for treating acne and method of using same |
FR3071M (en) | 1963-10-18 | 1965-01-18 | Centre Nat Rech Scient | New pancreatic proteases, usable in particular in gastroenterology. |
DE1517787A1 (en) * | 1965-12-06 | 1970-01-29 | Takeda Chemical Industries Ltd | Enzyme preparation and process for its production |
DE1617417A1 (en) * | 1966-12-08 | 1971-03-25 | Ciba Geigy | Pharmaceutical preparation |
US3860708A (en) * | 1973-11-15 | 1975-01-14 | Philips Corp | Method of delivering the intestines of human beings from bariumsulphate after barium meal examination |
US3940478A (en) * | 1974-04-29 | 1976-02-24 | Sutures, Inc. | Proteolytic enzymes as adjuncts to antibiotic prophylaxis of contaminated wounds |
GB1509866A (en) * | 1975-06-10 | 1978-05-04 | Johnson & Johnson | Enteric coated digestive enzyme compositions |
US4086257A (en) * | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
US4241046A (en) | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
DE2923279B1 (en) | 1979-06-08 | 1980-11-20 | Kali Chemie Pharma Gmbh | Process for the production of pancreatin pellets |
US4432975A (en) | 1981-04-13 | 1984-02-21 | Icn Pharmaceuticals, Inc. | Process for introducing vitamin B-12 into the bloodstream |
US5250418A (en) | 1981-10-06 | 1993-10-05 | Boehringer Mannheim Gmbh | Process and reagent for determining the activity of chymotrypsin and trypsin in feces |
DE3377506D1 (en) | 1982-12-30 | 1988-09-01 | Nordmark Arzneimittel Gmbh | Process for obtaining pancreatin |
WO1984002846A1 (en) | 1983-01-21 | 1984-08-02 | Advanced Drug Tech | Enzyme ointment |
US4447412A (en) | 1983-02-01 | 1984-05-08 | Bilton Gerald L | Enzyme-containing digestive aid compostions |
US4456544A (en) * | 1983-08-05 | 1984-06-26 | Vsesojuzny Nauchno-Issledovatelsky Biotecknichesky Institut | Enzyme-containing detergent composition for presterilization treatment of medical instruments and equipment |
US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
EP0616811A1 (en) * | 1985-12-03 | 1994-09-28 | T Cell Sciences, Inc. | Cell-free T cell antigen receptor and its clinical utilities |
US5023108A (en) | 1986-01-13 | 1991-06-11 | Research Corporation | Aqueous dispersions of waxes and lipids for pharmaceutical coating |
JPS62230714A (en) | 1986-03-31 | 1987-10-09 | Snow Brand Milk Prod Co Ltd | Enteric capsule |
US4826679A (en) * | 1986-05-23 | 1989-05-02 | Universite De Montreal | Composition and methods for alleviating cystic fibrosis |
DE3738599A1 (en) | 1987-11-13 | 1989-05-24 | Raps & Co Gewuerzwerk | Encapsulated dried yeast in particle form, process for the production thereof and use thereof |
WO1989008695A1 (en) | 1988-03-14 | 1989-09-21 | Novo-Nordisk A/S | Stabilized particulate composition |
CN1039706A (en) | 1988-08-04 | 1990-02-21 | 黄族和 | The preparation method of artificial Fa vegetable |
GB8821049D0 (en) | 1988-09-08 | 1988-10-05 | Health Lab Service Board | Method & composition for treatment & prevention of viral infections |
GB8923788D0 (en) | 1989-10-23 | 1989-12-13 | Unilever Plc | Enzymatic detergent compositions and their use |
PH30058A (en) | 1989-11-24 | 1996-11-08 | Biochemie Gmbh | Pancreation preparations |
CA2037178A1 (en) | 1990-02-28 | 1991-08-29 | Albert Walter Brzeczko | Deprenyl/l-dopa/carbidopa pharmaceutical composition |
US5618710A (en) * | 1990-08-03 | 1997-04-08 | Vertex Pharmaceuticals, Inc. | Crosslinked enzyme crystals |
NO920067L (en) | 1991-01-14 | 1992-07-15 | Ajinomoto Kk | FORADDITIVE FOR DRUGS |
US5607863A (en) * | 1991-05-29 | 1997-03-04 | Smithkline Diagnostics, Inc. | Barrier-controlled assay device |
US5190775A (en) * | 1991-05-29 | 1993-03-02 | Balchem Corporation | Encapsulated bioactive substances |
JPH04364119A (en) | 1991-06-11 | 1992-12-16 | Tsumura & Co | Bathing agent composition |
IL99628A (en) | 1991-10-02 | 2004-07-25 | Yissum Res Dev Co | Processes for the preparation of cyclic peptides, and pharmaceutical compositions containing them |
EP0614353A1 (en) | 1991-11-25 | 1994-09-14 | Richardson-Vicks, Inc. | Compositions for regulating skin wrinkles and/or skin atrophy |
US7242988B1 (en) * | 1991-12-23 | 2007-07-10 | Linda Irene Hoffberg | Adaptive pattern recognition based controller apparatus and method and human-factored interface therefore |
GB9207280D0 (en) | 1992-04-02 | 1992-05-13 | Unilever Plc | Skin care method and composition |
CA2136969C (en) * | 1992-06-12 | 2009-03-24 | Michael E. Lewis | Prevention and treatment of peripheral neuropathy |
US5460812A (en) | 1992-06-22 | 1995-10-24 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
US5260074A (en) * | 1992-06-22 | 1993-11-09 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
DE4227385A1 (en) * | 1992-08-19 | 1994-02-24 | Kali Chemie Pharma Gmbh | Pancreatin micropellets |
GB9218363D0 (en) * | 1992-08-28 | 1992-10-14 | Black & Decker Inc | Pivoting power tool with table |
DE4305460C2 (en) | 1993-02-23 | 1997-09-04 | Albert Dr Scheller | Pharmaceutical or cosmetic preparation containing enzymes, process for their preparation and their use |
JPH06339343A (en) | 1993-04-08 | 1994-12-13 | Ajinomoto Co Inc | Feed additive for ruminant |
TW310277B (en) | 1993-05-21 | 1997-07-11 | Pou Lin Fu Gin Pharm Co | The method of preparing enteric-coated pancreatin granules and its dosage forms |
DE4332985A1 (en) | 1993-09-28 | 1995-03-30 | Konrad Peter Maria Dr Sommer | Pharmaceutical composition for the treatment of exocrine pancreas dysfunction |
GB9403250D0 (en) | 1994-02-21 | 1994-04-13 | Univ Mcgill | Therapeutic use of myelin-associated glycoprotein (mag) |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US20080311554A1 (en) * | 1994-05-06 | 2008-12-18 | Slotman Gus J | Methods for monitoring patients with severe sepsis and septic shock and for selecting treatments for these patients |
US5527678A (en) * | 1994-10-21 | 1996-06-18 | Vanderbilt University | CagB and CagC genes of helicobacter pylori and related compositions |
US5476661A (en) | 1994-10-21 | 1995-12-19 | Elizabeth Arden Co., Division Of Conopco, Inc. | Compositions for topical application to skin, hair and nails |
AUPN033894A0 (en) | 1994-12-29 | 1995-01-27 | Rowe, J.B. | Prevention of adverse behaviour in humans and animals |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US6558708B1 (en) | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
CA2220451A1 (en) | 1995-05-17 | 1996-11-21 | Cedars-Sinai Medical Center | Methods and compositions for improving digestion and absorption in the small intestine |
US6562629B1 (en) | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
US5686311A (en) | 1995-06-23 | 1997-11-11 | The Children's Mercy Hospital | Diagnosis of autism and treatment therefor |
AU6682796A (en) * | 1995-07-21 | 1997-02-18 | New York University | Type ii phospholipase a2 and its use in killing gram-positive bacteria |
US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US6852487B1 (en) * | 1996-02-09 | 2005-02-08 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
JP2000506845A (en) | 1996-03-06 | 2000-06-06 | ノボ ノルディスク アクティーゼルスカブ | Method for killing or controlling microbial cells |
US5958875A (en) | 1996-03-29 | 1999-09-28 | The Regents Of The University Of California | Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity |
US5750104A (en) * | 1996-05-29 | 1998-05-12 | Digestive Care Inc. | High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith |
US5952178A (en) | 1996-08-14 | 1999-09-14 | Exact Laboratories | Methods for disease diagnosis from stool samples |
GB2318511A (en) * | 1996-10-23 | 1998-04-29 | Eurand Int | Process for the preparation of a pharmaceutical composition for rapid suspension in water |
US5860932A (en) * | 1996-10-24 | 1999-01-19 | Colin Corporation | Blood pressure monitor |
CA2190418A1 (en) | 1996-11-15 | 1998-05-15 | Zhi-Cheng Xiao | Neuron and neural tumor growth regulatory system, antibodies thereto and uses thereof |
US6100080A (en) | 1996-12-18 | 2000-08-08 | Novo Nordisk A/S | Method for enzymatic treatment of biofilm |
EP0966199A2 (en) | 1997-01-22 | 1999-12-29 | Kerry Ingredients (UK) Limited | Enzyme-based bread improvers |
CA2198317C (en) | 1997-02-24 | 2003-01-07 | Mouhsine El Abboudi | Method for preparing pancreatin which contains low amounts of residual organic solvent and product thereof |
UA64743C2 (en) * | 1997-03-13 | 2004-03-15 | Фьост Опініон Корпорейшн | System for managing disease process |
US5858758A (en) * | 1997-05-07 | 1999-01-12 | Incyte Pharmaceuticals, Inc. | Human serine protease precursor |
WO1998052593A1 (en) | 1997-05-19 | 1998-11-26 | Repligen Corporation | Method for assisting in differential diagnosis and treatment of autistic syndromes |
US6197746B1 (en) * | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
US6482839B1 (en) | 1997-06-02 | 2002-11-19 | Cellegy Pharmaceuticals, Inc. | Pyridine-thiols for treatment of a follicular dermatosis |
GB2347742B (en) | 1997-06-05 | 2001-11-07 | Royal Free Hosp School Med | Pharmaceutical composition for RBD |
CA2328503A1 (en) * | 1997-06-05 | 1998-12-10 | Royal Free Hospital School Of Medicine | Pharmaceutical composition containing transfer factor for treatment of inflammatory bowel disease and regressive behavioural disorder |
US20010006644A1 (en) | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
KR19990072826A (en) | 1998-02-26 | 1999-09-27 | 우재영 | A process for producing enteric-coated pancreatin granules |
EP1405570A1 (en) | 1998-03-04 | 2004-04-07 | Ajinomoto Co., Inc. | Process for producing ruminant feed additive composition |
US20010024660A1 (en) | 1999-09-29 | 2001-09-27 | Ismat Ullah | Enteric coated pharmaceutical composition and method of manufacturing |
US6020314A (en) | 1998-08-11 | 2000-02-01 | Milkhaus Laboratory, Inc. | Methods for treatment of neurological disorders |
DE69940821D1 (en) | 1998-10-09 | 2009-06-10 | Gen Mills Inc | Encapsulation of Sensitive Liquid Components in a Matrix for the Recovery of Discrete Particle-Stable Particles |
US6149585A (en) * | 1998-10-28 | 2000-11-21 | Sage Health Management Solutions, Inc. | Diagnostic enhancement method and apparatus |
US6168569B1 (en) * | 1998-12-22 | 2001-01-02 | Mcewen James Allen | Apparatus and method for relating pain and activity of a patient |
US6753306B2 (en) | 1998-12-23 | 2004-06-22 | Joseph J. Simpson | Germicidal and disinfectant composition |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
HUP0200556A3 (en) | 1999-03-17 | 2006-06-28 | Solvay Pharm Gmbh | Medicament for treating diabetes |
US7945451B2 (en) * | 1999-04-16 | 2011-05-17 | Cardiocom, Llc | Remote monitoring system for ambulatory patients |
US6210950B1 (en) * | 1999-05-25 | 2001-04-03 | University Of Medicine And Dentistry Of New Jersey | Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors |
US6153236A (en) | 1999-06-03 | 2000-11-28 | Balchem Corporation | Low melt encapsulation with high laurate canola oil |
JP2003502071A (en) | 1999-06-18 | 2003-01-21 | ブジャーナソン・ヨーン・ブラーギ | Fish serine proteinases and their use in medicines and cosmetics |
US7395216B2 (en) * | 1999-06-23 | 2008-07-01 | Visicu, Inc. | Using predictive models to continuously update a treatment plan for a patient in a health care location |
AU780567B2 (en) | 1999-08-13 | 2005-04-07 | James F. Cassily | Method and apparatus of enhancing learning capacity |
IL131508A (en) | 1999-08-19 | 2006-12-10 | David Cohen | Microencapsulated and controlled-release formulations of isoflavone from enriched fractions of soy and other plants |
US6187309B1 (en) * | 1999-09-14 | 2001-02-13 | Milkaus Laboratory, Inc. | Method for treatment of symptoms of central nervous system disorders |
US6447772B1 (en) | 1999-10-01 | 2002-09-10 | Klaire Laboratories, Inc. | Compositions and methods relating to reduction of symptoms of autism |
ES2194782T5 (en) | 1999-10-12 | 2014-08-20 | Oxoid (Ely) Limited | Improved procedure for the detection of acid-resistant bacteria of the genus Helicobacter in feces |
US6727073B1 (en) * | 1999-11-19 | 2004-04-27 | Binax, Inc. | Method for detecting enteric disease |
US20020103675A1 (en) * | 1999-11-29 | 2002-08-01 | John Vanelli | Apparatus and method for providing consolidated medical information |
US6534063B1 (en) * | 1999-12-17 | 2003-03-18 | Joan M. Fallon | Methods for treating pervasive development disorders |
US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
US6251478B1 (en) | 1999-12-22 | 2001-06-26 | Balchem Corporation | Sensitive substance encapsulation |
US6564104B2 (en) * | 1999-12-24 | 2003-05-13 | Medtronic, Inc. | Dynamic bandwidth monitor and adjuster for remote communications with a medical device |
US6980958B1 (en) * | 2000-01-11 | 2005-12-27 | Zycare, Inc. | Apparatus and methods for monitoring and modifying anticoagulation therapy of remotely located patients |
NZ520461A (en) * | 2000-02-14 | 2005-03-24 | First Opinion Corp | Automated diagnostic system and method |
US6261613B1 (en) * | 2000-02-15 | 2001-07-17 | General Mills, Inc. | Refrigerated and shelf-stable bakery dough products |
US7379885B1 (en) * | 2000-03-10 | 2008-05-27 | David S. Zakim | System and method for obtaining, processing and evaluating patient information for diagnosing disease and selecting treatment |
CA2342121C (en) * | 2000-03-29 | 2010-05-25 | Roquette Freres | Powdered mannitol and the procedure for preparing it |
US6399101B1 (en) * | 2000-03-30 | 2002-06-04 | Mova Pharmaceutical Corp. | Stable thyroid hormone preparations and method of making same |
AUPQ679100A0 (en) | 2000-04-07 | 2000-05-11 | Novapharm Research (Australia) Pty Ltd | Process and composition for cleaning medical instruments |
US6399114B2 (en) * | 2000-05-26 | 2002-06-04 | C & D Foreman, Inc. | Nutritional system for nervous system disorders |
US6783757B2 (en) * | 2000-06-01 | 2004-08-31 | Kirkman Group, Inc. | Composition and method for increasing exorphin catabolism to treat autism |
US20040062757A1 (en) | 2001-06-05 | 2004-04-01 | Finegold Sydney M. | Method of testing gastrointestinal diseases associated with species of genus clostridium |
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
US20070053895A1 (en) * | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
WO2002014537A2 (en) | 2000-08-14 | 2002-02-21 | Fallon Joan M | Methods for diagnosing and treating dysautonomia and other dysautonomic conditions |
US20020094367A1 (en) | 2000-09-08 | 2002-07-18 | Novozymes A/S | Dough composition |
WO2002019828A1 (en) | 2000-09-08 | 2002-03-14 | Novozymes A/S | A dough composition comprising a lipid-encapsulated enzyme |
IT1319655B1 (en) | 2000-11-15 | 2003-10-23 | Eurand Int | PANCREATIC ENZYME MICROSPHERES WITH HIGH STABILITY AND RELATIVE PREPARATION METHOD. |
US8030002B2 (en) * | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US20020119914A1 (en) | 2000-12-26 | 2002-08-29 | Deguang Zhu | New uses of insulin and pancreatin |
US6548556B2 (en) | 2000-12-27 | 2003-04-15 | Healthpoint, Ltd. | Stable enzymatic wound debrider |
GB2370839A (en) * | 2001-01-06 | 2002-07-10 | Benedikt Timmerman | Immunogenic complex useful for disease control |
CN1150032C (en) | 2001-01-15 | 2004-05-19 | 孙芳梅 | Concentrated granular medicine for treating baby diarrhea and its preparing process |
AR032392A1 (en) * | 2001-01-19 | 2003-11-05 | Solvay Pharm Gmbh | ENZYMES MIX, PHARMACEUTICAL PREPARATION AND USE OF PREPARED SAID. |
US7588757B2 (en) * | 2001-03-14 | 2009-09-15 | Genzyme Corporation | Methods of treating Parkinson's disease using recombinant adeno-associated virus virions |
US7107996B2 (en) * | 2001-04-10 | 2006-09-19 | Ganz Robert A | Apparatus and method for treating atherosclerotic vascular disease through light sterilization |
US7034134B2 (en) * | 2001-04-26 | 2006-04-25 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 |
US7232670B2 (en) | 2001-09-28 | 2007-06-19 | St. Jude Children's Research Hospital | Targeting proteins to cells expressing mannose receptors via expression in insect cells |
US7101573B2 (en) | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
US7630911B2 (en) * | 2001-10-24 | 2009-12-08 | Qtc Management, Inc. | Method of automated processing of medical data for insurance and disability determinations |
WO2003051345A2 (en) | 2001-12-14 | 2003-06-26 | Solvay Pharmaceuticals Gmbh | Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans |
US6797291B2 (en) | 2002-01-09 | 2004-09-28 | Balchem Corporation | Stable hygroscopic compositions and methods for stabilizing hygroscopic ingredients |
US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
ES2391381T3 (en) | 2002-05-03 | 2012-11-23 | Martek Biosciences Corporation | High quality lipids and methods for their production by enzymatic release from biomass |
US20040005304A1 (en) * | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
MXPA05001520A (en) * | 2002-07-08 | 2005-05-05 | Joe S Wilkins Jr | Antibacterial formulations. |
CA2501645A1 (en) | 2002-10-10 | 2004-04-22 | Diversa Corporation | Proteases, nucleic acids encoding them and methods for making and using them |
EP1413202A1 (en) | 2002-10-22 | 2004-04-28 | CSM Nederland B.V. | Lipid-encapsulated functional bakery ingredients |
US20050079594A1 (en) * | 2002-10-31 | 2005-04-14 | Karine Marion | Method of removing a biofilm |
US6835397B2 (en) | 2002-12-23 | 2004-12-28 | Balchem Corporation | Controlled release encapsulated bioactive substances |
US8946151B2 (en) * | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
JP2007523664A (en) | 2003-04-23 | 2007-08-23 | フェリング ベスローテン フェンノートシャップ | Sachet for pharmaceutical composition |
US7780595B2 (en) * | 2003-05-15 | 2010-08-24 | Clinical Decision Support, Llc | Panel diagnostic method and system |
EP1633400A2 (en) | 2003-05-16 | 2006-03-15 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
CN100487098C (en) | 2003-06-05 | 2009-05-13 | 柯积发 | Nanometer antibacterial non-phosphate washing powder |
ES2339351T3 (en) | 2003-06-19 | 2010-05-19 | Nicholas S. Bodor | IMPROVEMENT OF THE ACTIVITY AND / OR DURATION OF THE ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION. |
US7289761B2 (en) * | 2003-06-23 | 2007-10-30 | Cardiac Pacemakers, Inc. | Systems, devices, and methods for selectively preventing data transfer from a medical device |
US7354569B2 (en) * | 2003-07-11 | 2008-04-08 | Colgate-Palmolive Company | Chewable antiplaque confectionery dental composition |
BRPI0413076B8 (en) * | 2003-07-29 | 2021-07-27 | Abbot Laboratories Gmbh | analytical process for pancreatin and comparable compositions |
US7785584B2 (en) | 2003-08-13 | 2010-08-31 | Healthpoint, Ltd. | Ointment wound spray |
DK1663298T3 (en) * | 2003-09-23 | 2019-10-14 | Dsm Ip Assets Bv | APPLICATION OF PROLINE-SPECIFIC ENDOPROTEAS FOR HYDROLYSE OF PEPTIDES AND PROTEINS |
US7381698B2 (en) * | 2003-12-12 | 2008-06-03 | Chirhoclin, Inc. | Methods for treatment of acute pancreatitis |
US20050187130A1 (en) * | 2004-02-23 | 2005-08-25 | Brooker Alan T. | Granular laundry detergent composition comprising an anionic detersive surfactant, and low levels of, or no, zeolite builders and phosphate builders |
EP1729797B1 (en) | 2004-03-22 | 2008-09-10 | Solvay Pharmaceuticals GmbH | Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants |
US20050232894A1 (en) | 2004-04-20 | 2005-10-20 | Weiner Gregory M | Antimicrobial skin treatment composition and methods for producing and using an antimicrobial skin treatment composition |
ATE473010T1 (en) | 2004-05-24 | 2010-07-15 | Novozymes As | ENZYMES FOR PHARMACEUTICAL USE |
ITTO20040390A1 (en) | 2004-06-10 | 2004-09-10 | Roeder 1956 Farmaceutici S P A | COMPOSITION, IN PARTICULAR FOR PHARMACEUTICAL USE, WITH ANTIOXIDANT, ANTI-INFLAMMATORY AND IMMUNOSTIMULATING ACTION. |
EP1784160A1 (en) * | 2004-06-17 | 2007-05-16 | Amano Enzyme USA., Ltd. | Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers |
JP2008506464A (en) * | 2004-07-15 | 2008-03-06 | ノーススター ニューロサイエンス インコーポレイテッド | System and method for enhancing or influencing neural stimulation efficiency and / or efficacy |
EP1791966B1 (en) | 2004-09-10 | 2014-06-04 | Novozymes North America, Inc. | Methods for preventing, removing, reducing, or disrupting biofilm |
US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
JP4908420B2 (en) | 2004-10-14 | 2012-04-04 | アルタス ファーマシューティカルズ インコーポレイテッド | Composition comprising lipase, protease and amylase for treating pancreatic dysfunction |
CN101039667A (en) | 2004-10-15 | 2007-09-19 | 辉瑞大药厂 | Treatment of bipolar disorders and associated symptoms |
US20060115467A1 (en) | 2004-12-01 | 2006-06-01 | Pangborn Jon B | Compositions and methods for the treatment of autism |
US20070250119A1 (en) * | 2005-01-11 | 2007-10-25 | Wicab, Inc. | Systems and methods for altering brain and body functions and for treating conditions and diseases of the same |
US8187209B1 (en) * | 2005-03-17 | 2012-05-29 | Great Lakes Neurotechnologies Inc | Movement disorder monitoring system and method |
EP1861009B1 (en) * | 2005-03-17 | 2019-05-22 | Robert E. Coifman | Apparatus and method for intelligent electronic peak flow meters |
US20060294108A1 (en) * | 2005-04-14 | 2006-12-28 | Adelson Alex M | System for and method of managing schedule compliance and bidirectionally communicating in real time between a user and a manager |
US20070092501A1 (en) * | 2005-04-26 | 2007-04-26 | Prothera, Inc. | Compositions and methods relating to reduction of symptoms of autism |
US20060258599A1 (en) | 2005-04-27 | 2006-11-16 | Melanie Childers | Methods and composition for the treatment of cystic fibrosis and related illnesses |
AU2006252708A1 (en) | 2005-05-31 | 2006-12-07 | Orexigen Therapeutics, Inc. | Methods and compositions for managing psychotic disorders |
WO2007002572A2 (en) | 2005-06-24 | 2007-01-04 | N-Zymeceuticals, Inc. | Nattokinase for reducing whole blood viscosity |
WO2007014896A1 (en) * | 2005-07-29 | 2007-02-08 | Solvay Pharmaceuticals Gmbh | Processes for the manufacture of sterilized pancreatin powder |
US11266607B2 (en) * | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
RU2408364C2 (en) | 2005-08-15 | 2011-01-10 | Зольвай Фармасьютиклз Гмбх | Pancreatine micropellet nuclei to be entero-soluble coated |
US9198871B2 (en) * | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
US20100196344A1 (en) | 2005-10-14 | 2010-08-05 | Cystic Fibrosis Foundation Therapeutics, Inc. | Compositions and methods for treating pancreatic insufficiency |
US20070203426A1 (en) * | 2005-10-20 | 2007-08-30 | Kover Arthur J | Method and apparatus for obtaining real time emotional response data over a communications network |
WO2007053619A2 (en) | 2005-11-01 | 2007-05-10 | Bio-Cat, Inc. | A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency |
DK1965763T3 (en) | 2005-12-27 | 2020-02-10 | Univ Ramot | STABLE ENZYM PREPARATIONS AND METHODS FOR USE THEREOF |
US8728521B2 (en) | 2005-12-27 | 2014-05-20 | Hemant N. Joshi | Physically/molecularly distributed and/or chemically bound medicaments in empty, hard capsule shells |
RU2446210C2 (en) | 2006-02-02 | 2012-03-27 | ДСМ АйПи АССЕТС Б.В. | Food product containing proline-specific protease, its production method and its application for splitting toxic and allergenic gluten peptides |
US10072256B2 (en) * | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
JP2009541545A (en) | 2006-06-23 | 2009-11-26 | バーゼル・ポリオレフィン・イタリア・ソチエタ・ア・レスポンサビリタ・リミタータ | Catalyst precursor based on magnesium chloro alcoholate |
US20080019956A1 (en) | 2006-07-24 | 2008-01-24 | Manoj Kumar | Enzymatic prevention and control of biofilm |
US8287858B2 (en) | 2006-08-10 | 2012-10-16 | Jon Barron | Proteolytic enzyme formulations |
US20080057086A1 (en) * | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
DE102006053071A1 (en) | 2006-11-10 | 2008-05-15 | Ab Enzymes Gmbh | Protein-containing substance with increased temperature stability |
US8066986B2 (en) | 2007-02-01 | 2011-11-29 | Master Supplements, Inc. | Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms |
US20080199448A1 (en) | 2007-02-16 | 2008-08-21 | Ross Mairi R | Enzyme composition for improving food digestion |
PT2079445E (en) | 2007-02-20 | 2016-02-29 | Allergan Pharmaceuticals Internat Ltd | Stable digestive enzyme compositions |
US20090117180A1 (en) * | 2007-02-20 | 2009-05-07 | Giovanni Ortenzi | Stable digestive enzyme compositions |
US20090018407A1 (en) * | 2007-03-30 | 2009-01-15 | Searete Llc, A Limited Corporation Of The State Of Delaware | Computational user-health testing |
AU2008239737A1 (en) | 2007-04-13 | 2008-10-23 | Beth Israel Deaconess Medical Center, Inc. | Novel nutritional food products for improved digestion and intestinal absorption |
JP2008283895A (en) | 2007-05-16 | 2008-11-27 | Osaka City Univ | Method for detecting diarrheagenic escherichia coli |
US20090004285A1 (en) | 2007-06-29 | 2009-01-01 | Liangping Yu | Stable non-disintegrating dosage forms and method of making same |
US20110065628A1 (en) | 2007-08-27 | 2011-03-17 | University Of Virginia Patent Foundation | Medication Combinations for the Treatment of Alcoholism and Drug Addiction |
US20090063402A1 (en) * | 2007-08-31 | 2009-03-05 | Abbott Diabetes Care, Inc. | Method and System for Providing Medication Level Determination |
US20090110674A1 (en) | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
RU2356244C1 (en) | 2007-11-12 | 2009-05-27 | Федеральное государственное учреждение "Томский научно-исследовательский институт курортологии и физиотерапии Федерального агентства по здравоохранению и социальному развитию" (ФГУ "ТНИИКиФ Росздрава") | Combination therapy of children suffering from celiac disease at health resort stage |
US20090171696A1 (en) * | 2008-01-02 | 2009-07-02 | David Joseph Allard | System and method for patient portal with clinical decision intelligence |
WO2009109856A2 (en) | 2008-03-07 | 2009-09-11 | Axcan Pharma Inc. | Method for detecting infectious parvovirus in pharmaceutical preparations |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8976007B2 (en) * | 2008-08-09 | 2015-03-10 | Brian M. Dugan | Systems and methods for providing biofeedback information to a cellular telephone and for using such information |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
US20110104240A1 (en) | 2008-06-24 | 2011-05-05 | Micropharma Limited | Nitric Oxide Device and Method for Wound Healing, Treatment of Dermatological Disorders and Microbial Infections |
US20090324730A1 (en) | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
PL2318035T3 (en) | 2008-07-01 | 2019-10-31 | Curemark Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
WO2010025126A1 (en) | 2008-08-26 | 2010-03-04 | Cystic Fibrosis Foundation Therapeutics, Inc. | Rapidly disintegrating tablets comprising lipase, amylase, and protease |
US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
ATE541591T1 (en) | 2008-11-03 | 2012-02-15 | Nordmark Arzneimittel Gmbh & Co Kg | METHOD FOR REDUCING THE VIRAL AND MICROBIAL LOAD OF PANCREATIN |
BRPI1007379B8 (en) | 2009-01-06 | 2022-07-19 | Curemark Llc | pharmaceutical compositions for the treatment or prevention of oral infections by e. coli |
CA2747611C (en) | 2009-01-06 | 2019-09-17 | Curemark Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
JP2012518655A (en) * | 2009-02-23 | 2012-08-16 | アプタリス ファーマテック インコーポレイテッド | Controlled release composition comprising a proton pump inhibitor |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
WO2011000924A1 (en) | 2009-07-03 | 2011-01-06 | Abbott Products Gmbh | Spray-dried amylase, pharmaceutical preparations comprising the same and use |
EP2295039B2 (en) | 2009-08-28 | 2022-10-26 | Nordmark Pharma GmbH | Pancreatin pellets, in particular pancreatin micropellets and method for producing same |
US20110081320A1 (en) * | 2009-10-06 | 2011-04-07 | Nubiome, Inc. | Treatment/Cure of Autoimmune Disease |
WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
US20110112005A1 (en) | 2009-11-12 | 2011-05-12 | Alan Thomas Brooker | Laundry Detergent Composition |
CN107595828A (en) | 2010-01-15 | 2018-01-19 | 国立健康与医学研究所 | For treating the compound of autism |
CN102858795A (en) | 2010-02-02 | 2013-01-02 | 天野酶制品美国有限公司 | Use of proteases for gluten intolerance |
CN102884181A (en) | 2010-03-19 | 2013-01-16 | 加拿大阿普塔利斯制药公司 | Beta-propiolactone for inactivation of viruses in pharmaceutical pancreatic enzyme preparations |
ES2657673T3 (en) | 2010-10-01 | 2018-03-06 | Aptalis Pharma Limited | Enteric coated pancrelipase formulations, low intensity |
EP2616048A4 (en) | 2010-11-19 | 2014-04-02 | Curemark Llc | Preparation and use of combination enzyme and gastrointestinal modulator delivery systems |
EA026524B1 (en) | 2011-01-10 | 2017-04-28 | Общество С Ограниченной Ответственностью "Биолаб 612" | USE OF Toll-LIKE RECEPTOR AGONIST FOR TREATING CANCER |
GB2503852B (en) | 2011-04-21 | 2018-12-12 | Curemark Llc | Compounds for the treatment of neuropsychiatric disorders |
BR112014016557A8 (en) | 2012-01-03 | 2017-07-04 | Curemark Llc | Methods of treating behavioral symptoms of neurological and mental disorders |
CN104220088A (en) | 2012-02-02 | 2014-12-17 | 柯尔朗恩有限责任公司 | Enzyme compositions and use thereof for wound healing |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
-
2009
- 2009-08-04 US US12/535,676 patent/US10776453B2/en active Active
-
2020
- 2020-05-27 US US16/884,701 patent/US20200286620A1/en not_active Abandoned
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11033563B2 (en) | 2005-08-30 | 2021-06-15 | Curemark, Llc | Use of lactulose in the treatment of autism |
US11045527B2 (en) | 2008-03-13 | 2021-06-29 | Curemark, Llc | Method of diagnosing preeclampsia or pregnancy-induced hypertension |
US11235038B2 (en) | 2008-04-18 | 2022-02-01 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US11016104B2 (en) | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US11357835B2 (en) | 2009-01-06 | 2022-06-14 | Galenagen, Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US11419821B2 (en) | 2009-04-13 | 2022-08-23 | Curemark, Llc | Enzyme delivery systems and methods of preparation and use |
US10940187B2 (en) | 2011-04-21 | 2021-03-09 | Curemark, Llc | Method of treatment of schizophreniform disorder |
US11364287B2 (en) | 2012-05-30 | 2022-06-21 | Curemark, Llc | Methods of treating celiac disease |
US11020064B2 (en) * | 2017-05-09 | 2021-06-01 | LifePod Solutions, Inc. | Voice controlled assistance for monitoring adverse events of a user and/or coordinating emergency actions such as caregiver communication |
US11363999B2 (en) | 2017-05-09 | 2022-06-21 | LifePod Solutions, Inc. | Voice controlled assistance for monitoring adverse events of a user and/or coordinating emergency actions such as caregiver communication |
US11607182B2 (en) | 2017-05-09 | 2023-03-21 | LifePod Solutions, Inc. | Voice controlled assistance for monitoring adverse events of a user and/or coordinating emergency actions such as caregiver communication |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
US11147982B1 (en) | 2021-05-05 | 2021-10-19 | Kambix Innovations, Llc | Method and system for thermal stimulation of targeted neural circuits for neurodegenerative disorders |
US11404062B1 (en) | 2021-07-26 | 2022-08-02 | LifePod Solutions, Inc. | Systems and methods for managing voice environments and voice routines |
US11410655B1 (en) | 2021-07-26 | 2022-08-09 | LifePod Solutions, Inc. | Systems and methods for managing voice environments and voice routines |
Also Published As
Publication number | Publication date |
---|---|
US10776453B2 (en) | 2020-09-15 |
US20100169409A1 (en) | 2010-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200286620A1 (en) | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of parkinsons disease, movement and neurological disorders, and chronic pain | |
Sim | Mobile devices and health | |
Greiwe et al. | Wearable technology and how this can be implemented into clinical practice | |
Giacino et al. | Practice guideline update recommendations summary: disorders of consciousness: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research | |
Kvedar et al. | Digital medicine's march on chronic disease | |
Wicks et al. | Innovations in e-health | |
Espay et al. | Technology in Parkinson's disease: challenges and opportunities | |
Adams et al. | Mobile devices for the remote acquisition of physiological and behavioral biomarkers in psychiatric clinical research | |
de Lima et al. | Large-scale wearable sensor deployment in Parkinson’s patients: the Parkinson@ home study protocol | |
Robert et al. | Recommendations for ICT use in Alzheimer's disease assessment: Monaco CTAD expert meeting | |
Brichetto et al. | Beyond center-based testing: Understanding and improving functioning with wearable technology in MS | |
US20220246299A1 (en) | Electronic patient advisor and healthcare system for remote management of chronic conditions | |
Giesen et al. | Effects of an exercise program on physical activity level and quality of life in patients with severe alcohol dependence | |
Jauhiainen et al. | Identification of motor symptoms related to Parkinson disease using motion-tracking sensors at home (KÄVELI): Protocol for an observational case-control study | |
Lee et al. | Use of mobile apps for self-care in people with parkinson disease: systematic review | |
Lancioni et al. | Technology-based behavioral interventions for daily activities and supported ambulation in people with Alzheimer’s disease | |
Kim et al. | Future and development direction of digital healthcare | |
Kaye et al. | Using digital tools to advance Alzheimer’s drug trials during a pandemic: the EU/US CTAD Task Force | |
Sawyer et al. | Is inconsistent pre‐treatment bedtime related to CPAP non‐adherence? | |
Mitsi et al. | Implementing digital technologies in clinical trials: lessons learned | |
Pinarello et al. | Management of multiple sclerosis fatigue in the digital age: From assessment to treatment | |
Alberts et al. | A Randomized Clinical Trial to Evaluate a Digital Therapeutic to Enhance Gait Function in Individuals With Parkinson’s Disease | |
Castle | Despite active public health campaigns, death from falls increased 30% in the past decade: is ageism part of the barrier to self-awareness? | |
Mande et al. | Assessment of a mobile health iphone app for semiautomated self-management of chronic recurrent medical conditions using an N-of-1 trial framework: feasibility pilot study | |
Dhainaut et al. | Using connected objects in clinical research |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GALENAGEN, LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CURELON, LLC;REEL/FRAME:052768/0001 Effective date: 20170113 Owner name: CUREMARK LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FALLON, JOAN;FALLON, JAMES;HEIL, MATTHEW;AND OTHERS;SIGNING DATES FROM 20100303 TO 20100309;REEL/FRAME:052767/0104 Owner name: CURELON LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CUREMARK LLC;REEL/FRAME:052770/0323 Effective date: 20120315 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |